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Angiogenesis, the growth of new blood vessels from the pre-existing vasculature, is a 
pre-requisite for tumour growth and metastasis.  Tumour-angiogenesis is regulated by 
various pro- and anti-angiogenic factors released by both endothelial and tumour cells, as 
well as by the micro-environment.  Numerous studies have implicated various systems in the 
acquisition of the angiogenic phenotype.  The present study sought to investigate the role of 
the kallikrein-kinin system (KKS) in tumour-angiogenesis.   
 
The kallikreins consist of two serine proteases, plasma and tissue kallikrein (TK), involved in 
the release of kinin peptides by enzymatic cleavage of kininogens.  Stimulation of the 
cognate bradykinin receptors (BKR), B1R and B2R, mediates the mitogenic and vasoactive 
properties of kinins.  In addition, TK activates matrix metallo-proteinases (MMPs) involved 
in extracellular matrix (ECM) degradation.   
 
The expression profiles of TK and kinins have been found to be dys-regulated in numerous 
human cancers, and several studies have demonstrated the involvement of the KKS in growth 
and metastasis of prostate tumours.  Further, previous in vitro models in our laboratory have 
established an association between the KKS and prostate tumour-angiogenesis.  In those 
studies it was postulated that the up-regulated TK (produced by endothelial and tumour cells) 
stimulated endothelial cell proliferation.  Thus, the aim of the present study was to define the 
effects of the KKS and seek a direct correlation with angiogenesis using in vitro models with 





Ethical approval for this project was granted by the Biomedical Research Ethics Committee, 
University of KwaZulu-Natal (reference number BE152/08).  Micro-vascular endothelial 
cells represent a suitable in vitro angiogenic model and dermal micro-vascular endothelial 
cells (dMVECs) were obtained commercially for this purpose.  The tumour model used in 
this study was an immortalised prostate cancer (DU145) cell line.  The CM model involves 
the treatment of one cell line with the metabolites of another.  In the angiogenic model, 
dMVECs were exposed to increasing concentrations of DU145 CM.  Stimulation was further 
augmented with BKR agonists.  Specific BKR antagonists were used to test the specificity of 
stimulation.  In addition, vascular endothelial growth factor (VEGF) was tested as a positive 
proliferation control.  The potential of these agents to induce proliferation and migration was 
determined using the 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) 
assay and a modified Boyden chamber assay, respectively.  Previous studies investigating the 
pro-angiogenic effects of CM differed, in many respects, in terms of their models and 
methodologies.  In an attempt to fully explore the pro-mitogenic effects of CM on endothelial 
cells, various modifications, as well as alternate endothelial and tumour cell types, were 
employed in the present study.  The mitogenic and migratory effect of BKR agonists and 
antagonists on DU145 cells was also assessed.  Further, the tumour model was expanded to 
investigate the autocrine potential of the KKS, by investigating the effect of DU145 CM on 




In the angiogenic model, although the addition of DU145 CM elicited a statistically 
significant increase in micro-vascular endothelial cell proliferation, this increase was very 
small (<10%) and not dose-dependent.  Pre-incubation of dMVECs with a B1R or B2R 
antagonist did not influence this small effect of CM on proliferation.  In addition, neither 
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B1R nor B2R agonists, at any concentration, produced any significant proliferative effect on 
endothelial cells.  In contrast to these findings VEGF, a well-known mitogen, was able to 
stimulate proliferation of dMVECs.  Migration assays revealed that DU145 CM failed to 
stimulate endothelial cell motility.  Further, neither BKR agonist displayed any 
chemo-attractant potential in those assays.  
 
The most important finding was in the tumour model, where stimulation with a B1R agonist 
significantly enhanced proliferation and especially migration of DU145 cells.  In addition, 
pre-treatment with a B1R antagonist abolished both these effects.  B2R agonists could not 
produce the same positive effect as the B1R agonist on growth and migration of prostate 




Previous studies in our laboratory have shown prostate-tumour CM to promote proliferation 
of endothelial cells and have postulated that TK up-regulation may be the reason for this. 
However, the present study could not reproduce this effect of CM.  Further, BKR antagonists 
had no notable or consistent effect on the minimal promotion of proliferation that had been 
produced by DU145 CM.  In addition, selective BKR agonists failed to induce proliferation 
or migration of endothelial cells, key events in the angiogenic cascade.  Although in contrast 
to some studies, the present study was unable to implicate the KKS in angiogenesis, tumour 
neo-vascularisation is a consequence of several angiogenic factors functioning together as 
opposed to a single, isolated factor.  For example, we were able to demonstrate a positive 
mitogenic effect of VEGF on endothelial cells and it may be this as well as other factors in 
the CM that are responsible for the small proliferation we observed. 
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Up-regulation of kallikreins and kinins in tumours may enhance fundamental events in 
tumourigenesis in an autocrine manner, and bradykinin (BK) has previously been shown to 
promote tumour growth in mouse models.  Our study supported the involvement of the KKS 
in tumourigenesis.  Although CM from DU145 cells did not self-stimulate the migration of 
these cells, a B1R agonist enhanced both proliferation and migration, an effect that was also 
abrogated by the relevant antagonist, indicating a role for kinins.  In contrast to the findings 
of another study, stimulation of the B2R failed to significantly promote tumour growth or 
motility.  However, this is not an unexpected finding because it is thought that the ubiquitous 
B2R mediates physiological effects in the prostate while the inducible B1R plays a role in 
prostate cancer pathology. 
 
In summary, this study lends support to the ongoing exploration of BKR antagonists as 
possible candidates in the development of alternate approaches to cancer therapy.  This may 
be particularly beneficial to hormone-independent tumours, such as those of the prostate, for 
which there exists few effective treatment options. 
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CHAPTER 1 – LITERATURE 
1.1 Cancer 
1.1.1 History and definition 
The terms “cancer” and “tumour” are of Latin origin (1, 2).  It was Hippocrates (460-370 BC) 
who first associated the radiating veins of a breast tumour with the limbs of a crab, the Greek 
word for which was karkinoma and its subsequent Latin counterpart, cancer (2).  The word 
tumour initially made reference to “swelling” caused by inflammation (1).  In truth, not all 
swellings are tumours, thus, in the modern sense of the word, the term generally refers to a 
“new growth” or neoplasm (1, 3). 
 
Cancer encompasses an array of diseases with the capacity to involve virtually any organ 
system in the extensive animal kingdom (2, 4).  Although cancer awareness has progressively 
increased in the present era, it is by no means a new disease; ancient civilisations made 
reference to cancer in pictures and writings, while tumours have been detected in dinosaur 
bones and Egyptian mummies which date to approximately 150 million and 5000 years ago, 
respectively (2, 5).  In approximately 400 BC Hippocrates identified cancer as a 
disproportion of the black humour (from the spleen) over the three bodily humours - bile, 
phlegm and blood (6).  Although mistaken, his theory was the first to accredit the onset of 
cancer to natural causes; up until medieval times the belief that cancer was caused by various 
gods persisted (6).  Following the development of the microscope, knowledge of the 
biological basis of the disease progressed.  In the nineteenth century, Rudolph Virchow, a 
prominent pathologist, proclaimed that “every cell arises from another cell” (2, 5).  Although 
this statement holds true for normal cells in addition to cancer cells, it is only in tumours that 
cellular growth continues beyond normal development; subsequently, cancer was described 
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as a “cellular disease, where there was loss of normal control of cell proliferation” (6).  
Cancer development begins with normal cells undergoing several genetic aberrations, 
produced by various causative agents that impair their ability to appropriately respond to 
signals (intracellular and/or extracellular) that are responsible for proliferation, differentiation 
and irrevocable death (6).   
 
1.1.2 Epidemiology 
The worldwide burden of cancer is enormous with consequential human and financial costs 
(7).  In 2008, it was estimated that there were approximately 12.6 million new cancer cases 
globally (8).  After taking into account population size it was determined that cancer risk was 
twice as high in more developed countries than less developed nations (9).   
 
Prostate cancer is one of the most common malignancies among males in western countries 
(10, 11).  Towards the end of the twentieth century, worldwide prostate cancer incidence rose 
considerably (12).  Essentially, this could be attributed to the increased life expectancy, 
increased prevalence arising from exposure to carcinogens and/or increased detection through 
more frequent diagnostic use of prostate-specific antigen (PSA) (10, 12).  Asian countries 
where incidence rates were commonly low have since risen considerably, partly attributable 
to increasing westernisation of diet and lifestyle (10).  Table 1.1 shows the estimated 
worldwide and South African incidence and mortality rates for cancer.   
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Table 1.1: Estimated worldwide and SA incidence and mortality for cancer (2008) 
Cancer type Region Incidence
 x 1000 
Mortality 
 x 1000 




Prostate Cancer World 899 258 
 SA 7.6 2.5 
(*excluding non-melanoma skin cancer) 
Source: Adapted from (8) 
 
1.1.3 Aetiology 
1.1.3.1   Genetic, carcinogenic and risk factors 
Tumours have the capacity to develop from a single mutated cell (13).  The progression from 
normal cell to cancer cell is a multi-step process that involves both an individual’s genetic 
predisposition to cancer as well as external carcinogenic agents.  Carcinogens may be 
classified as chemical, physical or infectious agents, and can further be classified as 
genotoxic or non-genotoxic (14-16).  Genotoxic carcinogens induce DNA damage while 
non-genotoxic carcinogens mediate their effects by interference with growth factor 
expression or signal transduction pathways (17). 
 
Chemical carcinogens are rife and include asbestos, arsenic, constituents of tobacco smoke as 
well as hormones (13, 17).  Physical factors such as ultraviolet (UV) and ionising radiation 
are well established carcinogenic agents (16).  The primary effect of radiation appears to be 
the introduction of genetic instability, consequently promoting rare mutations and malignant 
transformation (15).  Viruses, eubacteria and helminths are the three types of organisms 
associated with cancer (13, 14).  These infectious agents are the second most prominent cause 
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of cancer worldwide and are commonly linked to stomach, liver and cervical malignancies 
(14). 
 
Despite its high incidence and morbidity, prostate cancer aetiology remains to be fully 
elucidated (10).  Its pathogenesis most likely involves interaction of both genetic and 
environmental factors (18).  Established risk factors include familial history, progressing age 
and ethnicity (12, 18).  Genetic factors are thought to contribute about 40% of the risk while 
progressing age increases the incidence exponentially (10).  In addition, factors such as 
androgens, diet, physical activity, sexual behaviour and obesity have been implicated in the 
aetiology of prostate cancer; however, their precise roles remain largely unclear (10, 12).   
 
1.1.3.2   Tumour suppressor genes and oncogenes 
Transformation of cells to the tumourigenic phenotype is a multi-stage process that involves 
mutations in two gene classes: oncogenes and tumour suppressor genes (19).  These genes are 
fundamentally involved in the life-cycle of a cell, from cell division to differentiation and 
ultimately death (20, 21). 
 
A mutation on one allele of a gene transforms the normal ‘proto-oncogene’ into the activated 
oncogene (20).  Oncogenic dominance may subsequently result in over-production of its 
growth stimulatory protein or an excessively active form thereof (20, 21).  Thus, oncogenes 
promote malignant transformation by encouraging cellular growth via the activation of 





Unlike oncogenes, tumour suppressor genes are recessive (23).  They contribute to malignant 
transformation when both alleles are inactivated by mutations (20, 21, 23).  Their resulting 
loss-of-function means the cell is denied suppressor proteins pertinent to cellular growth (20-
22). 
 
Numerous tumour suppressor genes and oncogenes thought to be involved in diverse cancers 
have been studied.  Several have been identified in prostate cancer; however, genes 
specifically and directly implicated in prostate tumour transformation and growth have yet to 
be established (24).  Tables 1.2 and 1.3 indicate oncogenes and tumour suppressor genes 
thought to be involved in prostate cancer. 
 
Table 1.2: Oncogenes involved in prostate cancer 
Oncogene  Gene Function Ref 
c-myc regulation of cell proliferation, differentiation and 
apoptosis 
(21, 24, 25) 
ERBB2 receptor tyrosine kinases involved in tumour growth (20, 24) 
BCL2 anti-apoptotic protein (20, 24) 





Table 1.3: Tumour suppressor genes involved in prostate cancer 
Tumour suppressor 
gene 
 Gene Function      Ref 
TP53 regulation of cell cycle, apoptosis (26) 
PTEN cell proliferation, apoptosis (20, 24) 
CDKN2A negative regulator of cell cycle (24, 27) 
CDKN1B cyclin kinase inhibitor (24) 
GSTP1 prevents DNA impairment due to 
carcinogenic agents and oxidants 
(28) 
NKX3.1 homeobox protein (29) 
 
1.1.4 Tumour development 
In normal human adults the balance between cell proliferation and cell death is tightly 
regulated.  Mutations in genes fundamental to cell cycle regulation lead to unrestrained cell 
proliferation and a disordered cell cycle, the fundamental trademarks of cancer (26).  In 
epithelial cancers tumour progression occurs in stages: (i) begins with a genetically-altered 
cell, (ii) progresses to hyperplasia, (iii) dysplasia, (iv) in situ cancer and (v) ultimately 
invasive cancer.  These stages, as described by Weinberg (1996), are further discussed below 
(21). 
 
The transformation from a normal to genetically altered cell with an increased capacity to 
proliferate initiates hyperplasia.  At this stage the mass of cells appear healthy but they 
proliferate excessively.  Years later a single cell from the growing mass undergoes an 
additional mutation that further reduces regulation of cell growth.  Hyperplasia subsequently 
progresses to dysplasia when the cells no longer appear normal.  In time, another mutation 
may further modify cell characteristics.  In situ cancer refers to a tumour that remains 
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enclosed.  However, with further mutations the growing tumour may acquire characteristics 
that enable penetration into underlying tissues advancing to invasive cancer.  In addition, 
cells may detach from the original site, enter blood and lymph vessels and metastasise.  
Secondary tumours may have fatal consequences when the functioning of vital organs is 
disturbed.  Malignant tumours differ from benign tumours in that they possess the capacity to 
invade adjacent tissue and metastasise.  This metastatic ability presents the greatest hindrance 
to successful cancer treatment (3). 
 
1.1.5 Conventional therapy 
Early detection is crucial to successful treatment and possible cure of cancer.  The screening 
and diagnosis of prostate cancer involves rectal examination, biopsy and the measurement of 
PSA, also known as human kallikrein 3 (hK3) (11, 30).  Conventional cancer therapy is 
dependent on the extent of malignancy and may involve surgery, radiation therapy and/or 
chemotherapy (3, 31, 32).  Since progression of prostate tumours is hormone-dependent, 
treatment of metastatic disease may also involve androgen-ablative therapy.  However, 
metastatic prostate cancers ultimately transform into hormone-independent forms of the 
disease (30).  In addition, chemotherapy has shown little positive effect in the treatment of 
prostate cancer (30).  Thus, novel, innovative approaches are needed for successful 
management of progressive prostate tumours. 
 
1.2 Angiogenesis 
The term angiogenesis describes the development of new capillary blood vessels from the 
pre-existing vasculature (33, 34).  In a normal adult, the rate of endothelial cell proliferation 
is lower than that of numerous other cell types in the body (35).  Angiogenesis does occur 
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under normal conditions however physiological angiogenesis is a tightly regulated process 
essential, and largely confined to embryogenesis, inflammation, wound healing and 
menstruation (34, 36, 37).  Dys-regulated angiogenesis is associated with several pathological 
conditions such as psoriasis, rheumatoid arthritis, diabetic retinopathy as well as cancer (35, 
38, 39).   
 
1.2.1 The angiogenic cascade 
Angiogenesis is a continuous process subdivided into several steps: (i) release of angiogenic 
factors, (ii) basement membrane degradation, (iii) endothelial cell migration, (iv) endothelial 
cell proliferation and (v) vessel differentiation (36, 39, 40).  These sequential events are 
further discussed below. 
 
(i) Release of angiogenic factors: Angiogenesis begins with the release of pro-angiogenic 
factors that have the capacity to act directly by binding to endothelial receptors subsequently 
activating them, or indirectly via stromal cells and macrophages (39-41).  In the past two 
decades, several angiogenic factors have been examined.  Their activity is further described 
in the sections that follow. 
(ii) Basement membrane degradation:  For endothelial cells to migrate into adjacent tissues 
the blood vessel basement membrane and surrounding extracellular matrix (ECM) must first 
be degraded (36, 39).  Numerous proteolytic enzymes such as plasminogen activators and 
matrix metallo-proteinases (MMPs) are involved in this process (36, 39, 41). 
(iii)  Endothelial cell migration:  ECM and basement membrane degradation create a clear 
course for endothelial cell assembly into a column to form ‘sprouts’ (37, 39).  The migratory 
process involves chemotactic movement, cytokines [interleukin-6 (IL-6), IL-8 and tumour 
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necrosis factor-alpha (TNF-α)] and growth factors [vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF)] (36, 39). 
(iv)  Endothelial cell proliferation: Angiogenic factors such as VEGF and basic FGF (bFGF) 
exhibit mitogenic activity (36).  This is essential to angiogenesis as sprouting blood vessels 
require further endothelial cells to develop (36).  
 (v) Vessel differentiation: blood vessel differentiation includes the formation of a new 
basement membrane and the recruitment of fibroblasts, smooth muscle cells and pericytes for 
vascular stability (34, 39).   
 
1.2.2 Angiogenesis and cancer 
While genetic and epigenetic changes are central to malignant transformation, another 
fundamental hallmark is vital to tumour progression, namely, the onset of angiogenesis which 
is known as the ‘angiogenic switch’(42). 
 
In 1971 Judah Folkman hypothesised that tumour growth was restricted in the absence of 
angiogenesis and extensive experimental evidence now supports this theory (43, 44).  
Newly-formed blood vessels are essential to tumour development beyond 1-2 mm3; they 
supply the growing mass with nutrients and oxygen while removing metabolic waste products 
(34, 40).  In addition, the blood capillaries present a channel permitting tumour cells to 
migrate from the primary tumour and form distant metastases (45).   
 
Tumour-angiogenesis differs significantly from physiological angiogenesis (42).  Tumour 
blood vessels lack an organised vascular structure, are characteristically immature and blood 
flow is irregular (36, 46).  They display increased permeability and are consequently termed 
‘leaky’ blood vessels (36).  A discontinuous endothelial cell lining, absent or undeveloped 
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basement membrane and a lack of accessory cells are essentially factors that contribute to 
hyper-permeability (46).  In addition, tumour cells have the capacity to imitate endothelial 
cells and are often found intermittently in the lining of tumour blood vessels (36). 
 
1.2.3 Regulation of angiogenesis 
Tumour-angiogenesis is an elaborate process that requires the involvement of numerous 
growth factors, cytokines and specific receptors (37).  Such factors involved in the regulation 
of angiogenesis are secreted by both endothelial and tumour cells as well as the surrounding 
stroma (34, 41).  It is this transforming ECM that creates a micro-environment suitable for 
endothelial proliferation, migration and invasion (30).  Pro-angiogenic factors are proteins 
that stimulate endothelial cell proliferation and motility whilst anti-angiogenic factors, often 
also secreted by dormant tumours, are inhibitory agents that prevent tumour growth (34).  
The balance between pro- and anti-angiogenic factors regulates the process of angiogenesis; 
the angiogenic switch occurs when such equilibrium is disturbed promoting pro-angiogenic 
expression (42).  Factors such as hypoxia, due to a proliferating tissue mass, and tumour 
suppressor and oncogene mutations tip the scale in favour of angiogenesis (46, 47). 
 
1.2.3.1   Pro-angiogenic factors 
VEGF 
VEGF, initially known as vascular permeability factor (VPF), is one of the most prominent 
pro-angiogenic factors central to both physiological and pathological angiogenesis (30, 42).  
The VEGF family consists of five isoforms: VEGF-A, VEGF-B, VEGF-C, VEGF-D and 
VEGF-E (48).  Additional members of the VEGF family include placental growth factor 
(PlGF-1 and PlGF-2) (36, 48).  Produced by diverse cell types, VEGFs are homo-dimeric 
23 
 
glycoproteins that mediate their effects via tyrosine kinase receptors (VEGFR-1, VEGFR-2 
and VEGFR-3) found on endothelial cells (36, 37, 49).  VEGF-A, commonly referred to 
simply as VEGF, has been the focus of intense research and is regarded as the most 
significant isoform in the tumour context (36, 49).   
 
VEGF is a key player in all events of the angiogenic cascade.  Important biological functions 
of VEGF include vascular hyper-permeability and its potent endothelial-cell specific 
mitogenic capacity (30, 50).  In addition, VEGF is involved in elongation, branching and 
survival of endothelial cells (31).  VEGF production is stimulated by cancer cell secretion of 
hypoxia-inducible factor 1 (HIF-1) which is produced in response to hypoxia (30, 51).  
Secreted VEGFs stimulate endothelial cells to release various proteases and plasminogen 
activators consequently resulting in basement membrane degradation (35, 52). 
 
VEGF expression is typically elevated in most human carcinomas and several studies have 
implicated VEGF in prostate cancer (53-56).  Doll et al. (2001) found that VEGF is present in 
low levels if not entirely absent in normal prostate tissues (53).  In contrast, raised VEGF 
concentrations were found in the plasma and urine of patients with prostate cancer (54).  In 
addition, Melnyk et al. (1999) found that a VEGF antibody diminished prostate cancer 
growth and metastasis in mice implanted with a DU145 cell line (57).  These findings 




Other pro-angiogenic factors 
Since angiogenesis is a complex process that involves numerous factors and signal 
transduction pathways, inhibition of one factor may result in angiogenic stimulation via other 
pro-angiogenic mediators (58).  Table 1.4 describes a variety of angiogenic stimulators 
involved in prostate cancer.  Some of these molecules such as those that belong to the VEGF 
family and the angiopoietins (Ang) are highly specific for endothelial cells.  Other angiogenic 
enzymes, chemokines and bFGF act on a variety of cells types while the angiogenic effect of 
indirect-acting molecules such as transforming growth factor beta (TGF-β) results from the 
secretion of other factors by macrophages, endothelial or tumour cells (35). 




• highly specific endothelial cell mitogen  
• induces vascular permeability; survival factor for neo-vessels 
(37, 59)
VEGF-B • in vitro endothelial cell mitogen (60)
VEGF-C • in vitro endothelial cell mitogen; induces vascular permeability (59)
VEGF-D • in vitro endothelial cell mitogen (61)
VEGF-E (orf virus) • endothelial cell mitogen; promotes vascular permeability (59)
PlGF • weak endothelial cell mitogen 
• weak inducer of vascular permeability
(59, 60)
bFGF / FGF-2 
• potent mitogen for numerous cell types including endothelial 
cells 
• induces endothelial cell migration 




• stimulates angiogenesis in vivo 
     (inhibits endothelial cell proliferation in vitro) 





• stimulates angiogenesis by production of prostaglandin E2 
which regulates production of VEGF
(31, 63)
PDGF • induces endothelial cell proliferation & migration (62)
Ang-1 • growth factor highly specific for endothelial cells 
• promotes PDGF production by endothelial cells
(64)
Ang-2 • agonist/antagonist activity 




• weak endothelial cell mitogen; induces VEGF expression (62)
Angiogenin • induces angiogenesis (31)
IL-8 • endothelial cell mitogen; stimulates endothelial cell migration (48)
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1.2.3.2   Anti-angiogenic factors 
Angiogenic inhibitors promote endothelial quiescence in several ways by: (i) inhibiting 
endothelial cell proliferation and migration, (ii) inhibiting ECM remodelling or (iii) promoting 
endothelial cell apoptosis (65).  Several endogenous angiogenic inhibitors have been 
discovered.  Table 1.5 summarises the anti-angiogenic factors involved in prostate cancer. 
Table 1.5: Anti-angiogenic factors associated with prostate cancer 
Anti-angiogenic factor Characteristic / Activity Ref 
Angiostatin 
• plasminogen fragment 
• specific endothelial cell inhibitor  
• inhibits angiogenesis and metastasis 
(31, 34) 
Endostatin 
• suppresses migration of endothelial 
cells 
• inhibits endothelial cell proliferation 
• induces apoptosis in endothelial cells
(34, 66, 67) 
PSA 
• converts plasminogen to active 
angiostatin-like fragment 
• inhibits proliferation, migration and 




• ECM protein 
• inhibits endothelial cell growth
(31, 70) 
IL-10 
• induces tissue inhibitors of metallo-
proteinase (TIMP) expression 
• inhibits MMP-2 expression 




1.2.4 Anti-angiogenic therapy 
Since angiogenesis is a pre-requisite for tumour growth and metastasis, anti-angiogenic 
therapy could essentially deprive the tumour of oxygen and growth factors, thereby 
diminishing its growth and spread (46).  Numerous in vivo studies using mouse models have 
demonstrated that tumour growth is diminished with the use of angiogenic inhibitors (72-74).  
Anti-angiogenic therapies have numerous advantages compared to conventional 
chemotherapy in that they are unlikely to display the side-effects (hair-loss and gastro-intestinal 
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complications) and drug-resistance observed with the use of current chemo-therapeutic agents.  
However, recent studies have demonstrated potential complications with the use of  
anti-angiogenic agents linked to physiological angiogenesis (75).  Currently there are 
approximately twenty angiogenic inhibitors being investigated in human trials of which three 
are being tested for their efficacy in prostate cancer (75).  These compounds may mediate 
their effects via different mechanisms which include: (i) inhibiting tumour cell secretion of 
angiogenic factors, (ii) inhibiting the pro-angiogenic activity of these tumour-secreted 
compounds, (iii) suppressing the endothelial cell activation in response to pro-angiogenic 
factors and (iv) stimulation of endogenous anti-angiogenic factors (48).  
 
1.3 Protease systems, cancer and angiogenesis 
Angiogenesis, tumourigenesis and metastasis are essentially processes that are initiated by a 
loss of normal control of cell growth and a shift in the balance of proteolytic and cell motility 
regulation (76).  The release of angiogenic stimuli and proteolytic enzymes that are involved 
in ECM degradation are crucial to these processes (76, 77).  Many of these extracellular 
proteolytic enzymes belong to either the serine protease family (plasminogen activators and 
kallikreins) or the MMP family (77).  These protease systems are discussed in greater detail 
in the sections that follow. 
 
1.3.1 The plasminogen-plasmin system 
The plasminogen-plasmin system is central to both physiological and pathological processes 
(78).  The system is comprised of plasminogen and two serine proteases, urokinase 
plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), as well as 
plasminogen activator inhibitors (PAI-1, PAI-2 and 2-antiplasmin) and a urokinase 
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plasminogen activator receptor (uPAR) (78, 79).  Serine protease plasminogen activators 
convert the inactive pro-enzyme, plasminogen to active plasmin (80).  PAI-1, PAI-2 and 
2-antiplasmin regulate the expression of plasminogen activators and plasmin, respectively 
(78).  Plasmin activation may initiate numerous pathways involving several activities: (i) it 
degrades the fibrin and fibronectin components of the ECM,  (ii) with or without membrane 
type MMPs (MT-MMPs), plasmin has the capacity to activate pro-MMPs (collagenases), 
thereby facilitating the remodelling of a key component of the basement membrane, Type-IV 
collagen, (iii) it may activate or stimulate release of growth factors such as VEGF, TGF-β 
and bFGF from the ECM and (iv) it has the capacity to generate kinins from high molecular 
weight kininogen (HMWK) (78, 81, 82).  ECM degradation, growth factor stimulation and 
bradykinin (BK) generation are key processes in both angiogenesis and tumourigenesis as 
well as metastasis (81, 83).  Several malignancies, including that of the prostate, display uPA 
and uPAR expression, the levels of which are typically up-regulated in progressive and 
invasive carcinomas (82). 
 
1.3.2 The matrix metallo-proteinase system 
The MMP family comprises more than twenty proteinases with the capacity to degrade 
elements of the ECM (84).  MMPs are released in their inactive form and so must first be 
cleaved to be activated (85).  Their activity can, however, be inhibited by TIMPs (78, 86).  
Abnormal MMP expression is associated with several pathological conditions including 
cancer, and several MMPs have been linked to tumour cell invasion and metastasis (84, 87).  
ECM degradation by MMPs contributes to angiogenesis by facilitating endothelial cell 
detachment and migration  (85).  In addition, they release angiogenic stimulatory factors such 
as VEGF, bFGF and TGF-β (87).   
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1.3.3 The kallikrein-kinin system 
The kallikrein-kinin system (KKS) is an endogenous cascade that is involved in the activation 
of polypeptides (88).  This complex system consists of kallikreins, kininogen, kinins, 
kininases and kinin receptors.  The kallikreins are a family of proteolytic enzymes, some of 
which have the ability to produce active kinin peptides from precursor kininogen molecules.  
Kinins mediate their numerous biological effects via their two cognate receptors, bradykinin 
receptor subtype 1 (B1R) and bradykinin receptor subtype 2 (B2R), and are rapidly 
metabolised by kininases (89).  Each of these components is discussed in greater detail in 
the following sections, and is further summarised in Figure 1.1. 
 
1.3.3.1   Kallikreins 
The kallikreins are a group of serine proteases found in biological fluids, neutrophils and 
glandular cells (89).  This group of enzymes can be divided into two major subsets: plasma 
kallikrein (PK) and tissue kallikrein (TK) (88, 90).  PK and TK differ in many aspects 
including their function and the type of kinin they generate (91).  In their respective roles PK 
generates BK from HMWK whereas activated TK generates kallidin (Lys-BK) from low 
molecular weight kininogen (LMWK) (92, 93).  However, in vitro TK forms kinins from 
both HMWK and LMWK (89).  The plasma KKS is involved in blood clotting, fibrinolysis, 
vascular tone regulation and inflammation while TK activation occurs during tissue damage, 
infection, disease and inflammation (89, 94).  In the sections that follow hK and KLK refer to 
the kallikrein protein and its related gene, respectively. 
 
1.3.3.2   Tissue kallikreins 
TK (hK1) was discovered in the 1930s as a pancreatic protein found in copious amounts 
however it was only until 1985 that the gene for this kallikrein (KLK1) was discovered (95).  
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Also in the 1980s, the human glandular kallikrein gene (KLK2) and PSA gene (KLK3) were 
identified (95).  During the last century a further twelve genes were discovered and 
designated as part of the kallikrein family (KLK4-KLK15), based on chromosomal location, 
sequence and structural resemblance to the first three genes (95, 96).  The primary focus of 
the present study, was hK1, and it is hereafter referred to as TK.  
 
Transcriptional regulation of kallikrein gene expression 
The kallikrein gene family consists of fifteen homologous kallikrein genes (91, 97).  A 
combination of hormonal and epigenetic factors are thought to be involved in the regulation 
of kallikrein gene expression (98).  KLK1, KLK6, KLK10 genes are up-regulated in response 
to oestrogens; however, KLK2 and KLK3 are up-regulated by androgens and progestins (99, 
100).  Steroid hormone receptor complexes control the transcription of genes either directly 
or indirectly (99).   In a direct approach, the steroid hormone receptor complex binds to 
hormone response elements (HRE) in the promoter/enhancer regions of the gene to assemble 
co-factors that collaborate with the transcription mechanism and regulate gene expression 
(99).  In contrast, HRE regulates gene expression indirectly by interacting with trans-acting 
transcriptional factors (99).  The KLK1 gene promoter bears a suspected oestrogen response 
element implicated in oestrogenic regulation (99).  Dys-regulated transcription of numerous 
kallikrein genes has been linked to numerous pathologies including cancer (98).   
 
Tissue kallikrein activation 
Since proteases catalyse reactions irrevocably, they are synthesised as zymogens and require 
proteolysis to be transformed into its active state (99).  Pro-TK has been reported to be 
activated by enterokinase, trypsin, trypsin-like kallikreins or by auto-activation in vitro (95). 
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Kallikrein expression and function 
KLK1 is expressed in a number of tissues; however, expression is greatest in the pancreas, 
kidney and salivary glands (81, 91, 101).  KLK2 and KLK3 are also expressed in various 
tissues but at comparatively higher concentrations in the prostate (100, 101).  KLK4-15 are 
not expressed in specific tissue types but many kallikreins have been broadly found to be 
expressed in endocrine-related organs.  Fourteen kallikrein genes are expressed in the breast, 
eight are expressed in the ovary and ovarian carcinoma cells while most are also expressed in 
the testis and prostate (96, 100). 
 
Members of the kallikrein family are involved in diverse enzymatic activities; however, only 
three kallikreins have a specific biological function (89, 96).  The presence of TK in diverse 
sites suggests its function may be different for particular cell types (89, 102).  In different cell 
types, kallikreins may possess one or many functions although the primary function of TK 
should be considered the release of kinins (89).  TK expression in the pancreas, pituitary and 
other tissues implicates this enzyme in growth factor and peptide hormone processing (99).  
In addition, TK cleaves several important proteins such as low-density lipoprotein, 
pro-insulin, atrial natriuretic factor, pro-renin, vasoactive intestinal peptide, angiotensinogen 
and pro-collagenase (89, 96).  Recent studies have implicated newly-discovered kallikreins in 
numerous physiological processes.  KLK4 has been implicated in enamelogenesis, KLK6, 10 
and 13 are thought to be involved in hormone processing in the pancreas while KLK6 and 8 
may contribute to myelination in the central nervous system (98). 
 
PSA (hK3) and hK2 demonstrate low kininogenase activity compared to TK (99).  The 
co-existence of hK2 and hK3 in tissues is indicative of a functional relationship (96).  
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Frenette et al. (1997) found that hK2 activates uPA in vitro (103).  Since uPA is associated 
with metastasis, it is likely that hK2 is also involved in this pathway in prostate cancer (100). 
 
1.3.3.3   Kininogen, kininases and kinins 
Kininogen 
Kininogens are single-chain glycoproteins synthesized by hepatocytes (89, 102, 104).   Thus 
far, two types of kininogens have been demonstrated in humans: HMWK and LMWK (81).  
LMWK and HMWK differ in size, structure and cleavage-susceptibility by TK and PK (89).  
LMWK has a molecular mass of 50-68 kDa (species-dependent) and comprises 409 amino 
acids while HMWK has a molecular mass of 88 to 120 kDa and comprises 626 amino acids 
(89). 
 
Kinins (kallidin and bradykinin) 
Kinins are active peptides released by enzymatic cleavage of kininogens by kininogenases 
(89, 105).  Cleavage of LMWK by TK releases kallidin while HMWK cleavage by PK 
produces BK.  Aminopeptidases are responsible for the conversion of some kallidin to BK 
(94, 106).  Kinins are multi-functional proteins that exhibit both physiological and 
pathological roles (107).  They are involved in physiological functions such as regulating 
local blood flow, blood pressure and glucose and electrolyte transport (108).  In addition, 
kinins are regarded as key players in inflammation and produce the fundamental features of 
inflammation: oedema, vasodilation and pain (81, 89, 108).  Further, kinins mediate cellular 
functions because they activate second generation mediators such as prostaglandins and 
noradrenaline (89).  They display potent mitogenic and chemokinetic potential in numerous 
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cell types and are thought to stimulate the motility of lymphocytes and tumour cells (11, 109, 
110).   
 
Kinin receptors 
Kinins mediate their numerous biological functions via their two receptors, B1R and B2R 
(104).  The kinin receptors differ in many respects, for example B2R are found only in some 
species (111).  The B2R is ubiquitous being expressed in respiratory, intestinal, ocular and 
cardiovascular tissues of mammals. These receptors are thought to mediate most 
physiological effects of kinins (102).  In contrast, the B1R is induced in numerous 
pathological states including inflammation and cancer (88, 92, 102).  B2R have a greater 
affinity for BK and kallidin while kinin derivatives, desArg9-BK and desArg10-kallidin, 
preferentially bind to B1R (88, 105).  
 
The genes coding for the two kinin receptors are found in a single locus located on 
chromosome 14, 12 kb apart and share a 36% homology (104, 112).  The B1R and B2R 
belong to the G-protein coupled receptor (GPCR) family and each consist of a polypeptide 
chain that traverses the membrane seven times, an extracellular amino terminus, an 
intracellular carboxy terminus,  and three extracellular and intracellular loops (102, 105, 112).  
 
Receptor signalling pathways 
Bradykinin receptors (BKR) are involved in mediating most of the biological functions of BK  
(109).  The signalling pathways of B1R and B2R are essentially similar (81).  Association of 
various G-proteins to kinin receptors activates phospholipase C and, therefore, second 
messengers such as calcium, diacylglycerol (DAG) and inositol triphosphate (105, 113).  An 
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increase in intracellular calcium may stimulate nitric oxide (NO) production, thereby, 
regulating blood pressure (112).  Calcium and/or DAG activates various protein kinase C 
(PKC) iso-enzymes involved in cell proliferation pathways (105).  In addition, activation of 
mitogen activated protein kinase (MAPK) pathways by GPCRs results in MAPK 
phosphorylation and subsequent activation of transcription factors involved in mitosis and 
DNA synthesis (105).  
 
Kininases 
Kinins have a short half-life in vivo and are quickly destroyed by peptidases soon after their 
systemic release (89).  Kininases are a family of peptidases that deactivate kinins and 
comprise kininase I [carboxypeptidase N (CPN) and carboxypeptidase M (CPM)] and 
kininase II [angiotensin I-converting enzyme (ACE) and neutral endopeptidase (NEP)] (81, 
89, 108, 114). 
 
1.3.3.4   Inhibitors and antagonists 
Tissue kallikrein inhibitors 
Serine protease inhibitors (serpins) have a high molecular weight and form specific and 
covalent bonds with TKs (102, 115).  By acting upon their proteases, serpins are involved in 
diverse physiological processes such as complement activation, coagulation, phagocytosis 
and fibrinolysis (116).  Many serpins exhibit functions separate from proteolytic regulation 
(116).  Kallistatin is a member of the serpin family that binds to TK and is expressed in 
diverse tissues, cells and fluids where it is involved in the regulation of TK activity (102, 
116).  It is however also involved in biological activities independent of the KKS (115).  No 
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clinical applications of TK inhibitors have been described in the literature thus far, although 
TK inhibitors with high specificities are available. 
 
Bradykinin receptor antagonists 
In order to determine the activity of cellular molecules specific antagonists are required that 
show high affinity for their receptors and no inherent activity (89).  In 1960, the structure of 
BK was correctly determined, following which Regoli and colleagues later reported the first 
B1R antagonist (102).  Several antagonists have since been synthesised by creating analogues 
of the BK molecule (89, 117).  Subsequent development of BKR antagonists has produced 
compounds with greater affinity for their targeted receptors, resistance to enzymic action and 
increased potency and action  (102).    
 
1.3.3.5   KKS in angiogenesis, cancer and prostate cancer angiogenesis 
Kallikrein-kinin system in cancer 
Research suggests that the kallikrein gene family is dys-regulated in cancer, for example, in 
ovarian cancer (95, 99).  Studies have also reported elevated kallikrein expression at mRNA 
or protein levels, in tumour cells compared to normal tissues (99, 118, 119).  In addition, 
kallikreins may function synergistically to induce tumour growth;  Prezas et al. (2006) found 
that simultaneous expression of kallikreins 4-7 in ovarian tumour cells inoculated into nude 
mice resulted in a 92% increase in tumour growth compared to the control group which did 
not express those kallikreins (120).  Kallikreins can exhibit both stimulatory and inhibitory 
effects on cancer cells and their micro-environment and this dual role is likely dependent on 
the type of tissue and tumour micro-environment (95).  Reports suggest that kallikreins may 
contribute to tumour progression by either direct or indirect stimulation (95).  Wolf et al. 
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(2001) demonstrated the involvement of TK in metastasis using in vitro Matrigel invasion 
assays where a TK inhibitor, FE999024, suppressed the invasion of MDA-MB-231 breast 
cancer cells into Matrigel by 33%.  They also found that the TK inhibitor was able to 
suppress the invasion of breast cancer cells using an ex-vivo assay of tumour-cell invasion in 
explanted rat lungs (121).  Previous studies have implicated other kallikreins in hormonal 
malignancies (96).  Steroid hormones have been linked to the aetiology of such malignancies 
and are also thought to be involved in kallikrein gene expression.  Thus, it is likely that 
kallikreins are linked to the steroid hormone-driven cascade that is triggered during tumour 
promotion and progression (99).  TK is expressed in several tumour cell lines and may be 
involved in carcinogenesis by enhancing cancer cell proliferation and increasing vascular 
permeability (99, 119, 122).  By releasing active kinin peptides TK stimulates vascular 
permeability, cell proliferation, metastasis and regulates angiogenesis (123-125).  BK 
demonstrates the potential to stimulate growth diversely; it may directly enhance tumour 
growth, promote angiogenesis via VEGF and bFGF release, and finally promote tissue 
permeability to aid tumour invasion by stimulating MMP activity (126).  Molina et al. (2009) 
demonstrated that specific stimulation of the B1R induced cell proliferation in breast cancer 
cells (127).  In addition, kallikreins may contribute to cancer independent of kinin 
production; Hecquet et al. (2000) demonstrated that kallikreins directly stimulated B2R 
(128).  BK, prostaglandins and NO are key players in promoting vascular permeability in 
tumour tissues and nourishing tumour growth (129).  Wu et al. (2002) found that the B2R is 
expressed in several human cancers, suggesting a role for BK in the growth and progression 





Various components of the KKS are also expressed in prostate cancer (101, 119, 124, 131).  
Using an in vitro cell proliferation assay, Barki-Harrington and Daaka (2001) found that BK 
stimulates the proliferation of prostate cancer, cells thereby, implicating BK in the 
patho-physiology of prostate cancer (109).  Taub et al. (2003) demonstrated the expression 
pattern of kinin receptors in human benign and malignant prostate specimens (11).  Their 
report indicates that the B2R is non-selectively expressed.  In contrast, the B1R was only 
found in prostatic intra-epithelial neoplasia and malignant tissues but not in benign prostate 
specimens.  In addition, Taub and colleagues found that stimulation of the B1R, using a 
selective agonist, significantly enhanced growth, migration and invasion of prostate cancer 
PC3 cells.  Further, the addition of a B1R antagonist abrogated such effects.  These data 
indicate that the B1R mediates growth, migration and invasion of prostate cancer cells and 
further implicates the B1R in prostate cancer metastasis.  Barki-Harrington et al. (2003) 
suggested the presence of B1R-B2R complexes in prostate cancer cells and found that 
antagonism of one receptor disturbs the cellular response of the other receptor (132).  Thus 
the interaction between both BKR sub-types may be vital for the proliferation of prostate 
cancer cells.  In addition, BK antagonist peptides have demonstrated anti-cancer activity in 
athymic nude mice implanted with prostate cancer cells (126). 
 
Kallikreins as cancer biomarkers 
Considerably more hK2, hK3 and hK4 are expressed in the prostate compared to other tissues 
(90).  This tissue-specific expression of these kallikreins and their release into biological 
fluids qualify them as excellent biomarkers for prostatic diseases (90).  The most significant 
and well-established cancer biomarker for the diagnosis and monitoring of prostate tumours 
is hK3 (PSA).  However, PSA is limited in its capacity to differentiate between pre-malignant 
lesions such as benign prostatic hyperplasia and prostate cancer (97, 133).  Recent studies 
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suggest that other kallikreins may have potential as biomarkers in cancer and other 
pathologies (97, 98).  In addition, KLK5 and KLK11 as well as hK11 show promising 
potential as prognostic or diagnostic markers in prostate cancer (97, 134). 
 
KKS in angiogenesis 
Kallikreins may promote angiogenesis by modulating hallmarks such as the angiogenic 
switch, endothelial cell proliferation and migration, direct or indirect ECM degradation and 
blood vessel formation (95).  Miao et al. (2002) found that kallistatin inhibited VEGF or 
bFGF-induced endothelial cell proliferation, migration and adhesion (116).  In addition, TK 
indirectly facilitates ECM degradation by activating two Type-IV collagenases (pro-MMP-2 
and pro-MMP-9) which are involved in the breakdown of collagen and other elements of the 
basement membrane (96, 135).  TK expressed in angiogenic endothelial cells is involved in 
the production of kinins which consequently stimulate angiogenesis (125, 136).  Emanueli et 
al. (2001) found that upon inducing hind-limb ischemia in mice, capillary density increased 
and kinin B1R expression was induced (136).  That study also demonstrated that human TK 
gene delivery by injection of adenovirus resulted in a heightened ischemia-induced 
angiogenic response; and antagonism of the B1R resulted in an attenuated angiogenic 
response, however, antagonism of the B2R proved fruitless.  Recently, Yao et al. (2008) 
demonstrated that TK administration promoted neo-vascularisation in the infarcted 
myocardium of a rat while Stone et al. (2009) demonstrated diminished growth of the 
vasculature following hind-limb ischemia in TK-knockout mouse studies (137, 138).  
Growing scientific evidence indicates that BK may be a primary modulator of 
tumour-angiogenesis and consequential tumour progression; however, the exact mechanism 
of action remains to be fully elucidated (139).  Ishihara et al. (2001) demonstrated that BK 
enhanced tumour-associated angiogenesis and tumour growth in mice implanted with 
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sarcoma 180 cells (140).  That group found that a selective B2R antagonist suppressed 
tumour-angiogenesis and tumour growth while a B1R antagonist failed to do so.  They later 
demonstrated a role for BK in tumour-angiogenesis in which their results suggest that BK 
enhanced angiogenesis by promoting tumour vascular permeability (141).  Recently, Wright 
et al. (2008) reported the presence of TK, B1R and B2R in the membrane projections of both 
endothelial and prostate cancer cells in vitro and found that the addition of tumour cell 
metabolites to the endothelial cells stimulated their proliferation (119).  That group also 
demonstrated elevated concentrations of TK released by dermal micro-vascular endothelial 
cells (dMVECs) when challenged with DU145 conditioned medium (CM).  They speculated 
that the KKS may be central to prostate cancer progression either directly or indirectly by 
enhancing angiogenesis. 
 
1.4 Angiogenic models 
In 1971 Judah Folkman proposed the importance of angiogenesis in tumour growth (142).  
Almost a decade later,  he and a colleague were the first to observe angiogenesis in vitro 
(143). Targeting the micro-vasculature has become the subject of numerous studies in the 
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Figure 1.1: Overview of the KKS 
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1.4.1 In vivo models 
1.4.1.1   Chorioallantoic membrane assay 
The chorioallantoic membrane (CAM) assay is the most commonly used in vivo angiogenesis 
assay to investigate the potential of a test substance to induce the development of blood 
vessels (144).  Since chick embryos that are 7-8 days old lack an established immune system, 
this model allows for the investigation of tumour-angiogenesis (145).  Briefly, it involves an 
angiogenic or anti-angiogenic test substance within a gelatin or collagen sponge support that 
is inserted onto the membrane (146).  The angiogenic effect of the compound can then be 
assessed by determining the number of new blood capillaries via visual or computer-assisted 
methods (146, 147).   
 
1.4.1.2   Corneal assay 
The rationale behind the corneal angiogenesis assay is that since the cornea is normally a 
non-vascular site, any new blood vessels produced would be in response to the experimental 
substance (148, 149).  A ‘pocket’ is surgically created in the corneal stroma (rabbits, rats or 
mice models), into which the angiogenic substance is inserted (146, 150).  The angiogenic 
response can then be assessed via visual or computer-assisted methods (146). 
 
1.4.1.3   The dorsal air sac model 
The dorsal air sac model is used to assess the angiogenic effect of tumour cells (145, 149).  A 
suspension of tumour cells is inserted into a sub-cutaneous chamber (dorsal air sac) in rats or 
mice and allowed to form a tumour mass (151).  A test substance is usually administered, and 
the exposed area of the tumour can be assessed in terms of the angiogenic effect by counting 
the number of new blood capillaries (147). 
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1.4.2 In vitro models 
1.4.2.1   Two-dimensional and three-dimensional models 
Two-dimensional (2-D) models are those in which endothelial cells grow parallel to the 
surface of the plastic culture dish on which they are seeded and can be used to evaluate key 
processes in angiogenesis (152).  Proliferation, migration and the formation of cord-like 
structures by endothelial cells have been the primary focus of in vitro angiogenic models 
(145).  Using this model, the effect of stimulatory and inhibitory compounds such as CM, 
receptor agonists and antagonists can be investigated.  .  
 
The proliferative effect of a test substance on endothelial cells can be assessed both directly and 
indirectly with the use of (i) a haemocytometer, (ii) an electric Coulter counter, (iii) thymidine 
incorporation or (iv) 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT), a 
yellow tetrazolium salt (145, 153).  Proliferation assays, therefore, have the advantage of being 
simple, reproducible and quantifiable using high-throughput methods (147, 154).  
 
The Boyden chamber assay is the most frequently used model for endothelial cell migration 
(146, 154).  Endothelial cells migrate by chemotaxis in response to angiogenic stimulatory 
factors (145).  Briefly, the upper chamber contains the endothelial cells while the lower 
chamber contains the chemo-attractant.  The upper and lower chambers are separated by a 
porous polycarbonate filter allowing only the movement of cells (150, 155).  Cells that have 
migrated can further be stained and counted, or high-throughput methods such as fluorescent 
detection may be employed (146, 155).  Alternatively, migration may be evaluated using the 
“wound healing” assay which involves scraping off the endothelial cell monolayer and 
subsequent quantification of endothelial cells that have migrated into the disrupted area 
(147).   
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The formation of tube-like structures is demonstrative of later events in the angiogenic 
cascade and can be investigated by seeding endothelial cells onto a matrix such as Matrigel, 
fibrin or collagen (147, 153).  Test substances may be added to the growing vessels to 
evaluate their angiogenic potential and their effects on tubule length and density can be 
assessed using image-analysis (146).  These differentiation assays can be investigated in both 
2-D or three-dimensional (3-D) models depending on the organisation of the tube-like 
structures within the matrix (146, 152).  While 2-D models improve our knowledge of the 
ECM, 3-D models are a better representation of angiogenesis in the in vivo milieu, as 
endothelial cells have the capacity to proliferate, migrate and differentiate in the matrix of 
3-D models (152). 
 
1.4.3 Advantages and limitations of in vivo and in vitro models 
Essentially, angiogenic assays should be simple, inexpensive and reproducible with 
high-throughput quantitative analysis (146).  Although some in vitro models meet these 
requirements, previous studies have demonstrated that a substance regulating events in the 
angiogenic cascade in vitro may not reproduce the same effect in vivo (35, 145, 154).  The 
angiogenic effect of a test substance should, therefore, eventually be established with the use 
of more complex models (146, 148).  In addition, while the endothelial cell is the primary 
element of angiogenesis, several other supporting cells, as well as the blood and ECM 
contribute to the process (147).  Thus, in vivo studies investigating angiogenesis are 
fundamental phases in drug research and development.  However, in vivo assays have many 
disadvantages in that they are complicated, often use non-human models, sometimes require 
surgical skills, are time consuming, expensive and difficult to reproduce (146, 153).  Further, 
tissue injury following implantation of test substances may induce inflammation, thereby 
altering results (146).  
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1.4.4 Models used in the present study 
Taking into consideration the resources available, in vitro models were chosen in the present 
study because they are simple, relatively inexpensive and reproducible.  In addition, in vitro 
models allow for the specific investigation of test substances in an isolated system (154).  
Micro-vascular endothelial cells were initially selected for use in the angiogenic assays 
because they are more representative of the in vivo environment than endothelial cells of 
macro-vascular origin; however since dMVECs demonstrated little angiogenic capacity the 
angiogenic potential of human umbilical vein endothelial cells (HUVECs) was later explored 
(147).  Accordingly, angiogenic 2-D models involving MTT proliferation and Boyden 
chamber migration assays were selected to investigate the effect of various test substances on 
the growth and motility of endothelial and tumour cells.  A CM approach was used, whereby 
the medium from one cell type (which contains mediator substances secreted by those cells) 
is added to other cells (122).  Tumour metabolites released by proliferating cancer cells were 
thereby presented to endothelial cells at increasing concentrations.  Using commercial BKR 
agonists and antagonists, components of the KKS were also tested for their ability to 
stimulate or inhibit proliferation and migration of endothelial and tumour cells. 
 
1.5 Rationale, aims and objectives 
Previous studies using cultivated cells and CM have shown that when endothelial cells are 
exposed to increasing concentrations of prostate and breast tumour cell metabolites, dMVEC 
proliferation and TK production was enhanced (156).  Thus, those investigators proposed that 
the KKS may be involved in tumour-angiogenesis.  Accordingly, the present study aimed to 
further investigate the association between the KKS and angiogenesis/tumourigenesis by 
seeking a direct link that kinins may exert on endothelial and tumour cell proliferation and 
migration using CM, kinin receptor agonists and antagonists. 
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The objectives were to establish in vitro tumour-angiogenic models and use these to 
determine the effects of tumour CM and BKR agonists and antagonists on the following 
angiogenic and tumourigenic processes: 
1. endothelial cell proliferation  
2. endothelial cell migration  
3. tumour cell proliferation 
4. tumour cell migration 
 
1.6 Hypothesis 
Tumour-induced KKS promotes endothelial and tumour cell growth and motility, 







MATERIALS AND METHODS 
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CHAPTER 2 - MATERIALS AND METHODS 
2.1 Ethical approval 
Ethical approval for this project was granted by the Biomedical Research Ethics Committee, 
University of KwaZulu-Natal, reference number BE152/08. 
 
2.2 Cell culture 
2.2.1 Cell lines and culture media 
2.2.1.1   Endothelial cell lines 
The dMVEC line was commercially-obtained from Clonetics (BioWhittaker, Walkersville, 
USA).  The frozen 1 ml aliquot was preserved and transported on dry ice.  The primary 
culture specifications revealed that (i) they were harvested from a 42 year old black female 
donor in 2007, (ii) the cells were in their third passage with cell viability at 82% and a cell 
count of 1.2 x 106 per ml, and (iii) the human immunodeficiency virus (HIV), hepatitis B 
virus (HBV) or hepatitis C virus (HCV) was not detected.  The cryo-vial was stored at -85oC 
in an ultra-freezer (Ultralow Freezer, NuAire, USA) for future use.  Commercially-obtained 
HUVECs were kindly donated by the Department of Medical Microbiology, University of 
Kwa-Zulu Natal.   
 
2.2.1.2   Endothelial cell media 
EGM®-2MV Bulletkit (micro-vascular endothelial growth medium-2) cell culture media was 
purchased from Clonetics.  The product consisted of a basal medium (EBM-2) supplemented 
with fetal bovine serum (FBS, 25 ml), hydrocortisone (0.2 ml), bFGF (2 ml), VEGF (0.5 ml), 
R3-insulin-like growth factor-1 (R3-IGF-1, 0.5 ml), ascorbic acid (0.5 ml), EGF (0.5 ml) and 
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gentamicin sulphate amphotericin β (GA-1000, 0.5 ml), under aseptic conditions.  
Re-constituted medium had a shelf-life of 3 months at 4oC.  For clarification, EGM-2 
consists of basal medium supplemented with growth factors whereas medium free of growth 
factors is referred to as EBM-2.  EGM-2 and EBM-2 may be serum-free or supplemented 
with FBS. 
 
2.2.1.3   Tumour cell lines 
The human prostate adenocarcinoma (DU145), cervical adenocarcinoma (HeLa) and brain 
neuroblastoma (N2α) cell lines are immortal cell lines that have been continuously passaged 
and maintained within the Department of Therapeutics and Medicines Management, 
University of KwaZulu-Natal, South Africa, for several years.  DU145 and HeLa are both 
aneuploid, epithelial cell lines.  DU145, is a metastatic, androgen-independent cell line that 
was harvested from the brain of a 69 year old Caucasian male while HeLa, was originally 
isolated from a 31 year old black female (Henrietta Lacks, abbreviated to HeLa) (157, 158).  
Frozen cryo-vials of tumour cells were stored at -85oC in an ultra-freezer (NuAire, USA) for 
future use. 
 
2.2.1.4   Tumour cell media 
DU145 and HeLa cell culture medium consisted of Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% FBS, penicillin-streptomycin-fungizone (PSF, 100 µg/ml) 
and L-glutamine (2 mM) (BioWhittaker).  N2α medium additionally contained sodium 
pyruvate (2 mM) (BioWhittaker).  Tumour media was prepared under aseptic conditions, and 
thereafter stored at 4oC for a maximum of 2-3 weeks.  
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2.2.2 Receptor agonists and antagonists in the present study 
Selective B1R and B2R agonists were commercially-obtained from Tocris Bioscience, USA.  
The B1R agonist (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe) has a molecular weight of 
1032.21 g/mol while the B2R (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-ψ(CH-NH)-Arg) has a 
molecular weight of 1046.23 g/mol.  The B1R antagonist, des-Arg9-[Leu8]-BK acetate salt and 
B2R antagonist, Hoe 140, were purchased from Sigma-Aldrich, USA.  des-Arg9-[Leu8]-BK 
acetate salt and Hoe 140 are selective BKR antagonists that have molecular weights of 
870.01 g/mol and 1304.52 g/mol, respectively.  des-Arg9-[Leu8]-BK is the most extensively 
used B1R antagonist in experimental studies.  Similarly, Hoe 140 has been used in several 
studies, both in vivo and in vitro, as a basic prototype of the B2R antagonist (102, 111).   
 
2.2.3 Aseptic technique 
Cell culture and media preparation were always performed under sterile conditions in a 
class II biological safety cabinet (Labotec, Durban, South Africa).  Disposable pasteur 
pipettes (LASEC, Durban, South Africa) and plastic pipette tips (Greiner Bio-One, Austria) 
were sterilised by autoclaving (Speedy autoclave, Hirayama, Japan) at 121oC for 20 minutes.  
Pipetting aids consisted of an electronic pipette (Powerpette Plus; Jencons, USA) and 
mechanical pipettes (Gilson, France).  Prior to work commencing the safety cabinet was 
exposed to UV irradiation for at least half an hour.  Although the exposed working surfaces 
are sterilised by UV irradiation, its effectiveness is, however, limited because it is unable to 
reach crevices; the sterilising procedure is thus supplemented with the use of alcohol (159).  
All working surfaces and equipment were swabbed with 1% medical disinfectant solution 
(Virkon; Antec, South Africa) followed by 70% ethanol solution (Merck, South Africa).  
Consumables used during cell culture were swabbed with 70% ethanol before being 
introduced into the safety cabinet. 
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2.2.4 Thawing, seeding and maintenance of cell cultures 
Tissue culture dishes, 60 mm (21 cm2) or 100 mm (55 cm2) (Corning-Costar, USA), were 
pre-primed with appropriate volumes (4 ml and 8 ml, respectively) of cell-specific medium, 
and incubated for approximately 30 minutes in a humidified CO2 incubator (Function Line; 
Heraeus, Germany) calibrated at 37oC, 5% CO2.  Cryo-frozen cells, stored in 1.8 ml 
cryo-vials (Corning-Costar, USA), were individually removed from the ultra-freezer and 
allowed to thaw by regular agitation for a maximum of 3 minutes in a 37oC water-bath (The 
Scientific Group).  Care was taken not to immerse the cryo-vial below the seal to prevent 
potential water-borne contamination.  The cryo-vial was swabbed, introduced into the sterile 
cabinet and the contents pipetted into the pre-warmed tissue culture dish.  The culture dish 
was swirled gently to allow even distribution of cells.  In order to build cell banks, tumour 
cells and dMVECs were seeded at a density of 6000 cells/cm2.  Culture dishes were then 
incubated overnight in a humidified CO2 incubator (Function Line; Heraeus, Germany) at 
37oC, 5% CO2 to allow surface attachment.  A media change was performed with fresh, 
pre-warmed medium.  The cells were further incubated at 37oC, 5% CO2.  Nutrients and 
growth factors were subsequently replenished every alternate day by performing a media 
change.  The following formula was used to calculate the volume of cell-suspension required 
to determine the appropriate seeding densities:   
 
Cell-suspension volume (ml) = [seeding density (cells/cm2) x surface area of culture dish (cm2)]  
      concentration of viable cells (cells/ml) 
 
Cell cultures were examined using a phase-contrast, bright-field inverted microscope (DMIL; 
Leica, Germany) and their contaminant-free growth, health and morphology recorded 
regularly.  Upon attaining 70-80% confluency, cells were harvested and subsequently (i) 
sub-cultured for further cell propagation or (ii) cryo-frozen to build a cell bank. 
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Figures 2.1 and 2.2 demonstrate confluent dMVECs and DU145 in culture as visualised by 
phase-contrast microscopy. 
 
2.2.5 Sub-culturing and cryo-storage 
Cells were enzymatically disaggregated using trypsin-versene (BioWhittaker, Walkersville, 
USA).  Spent medium was aspirated and discarded.  The culture dish was subsequently rinsed 
and gently swirled for approximately 30 seconds with pre-warmed Hanks Balanced Salt 
Solution (HBSS; BioWhittaker, Walkersville, USA) to remove cell debris and any remaining 
serum.  The HBSS was aspirated and discarded.  Trypsin-versene, (2 ml and 4 ml for a 
60 mm and 100 mm culture dish, respectively), pre-warmed to 37oC, was added to the culture 
dish and incubated at 37oC, 5% CO2 for approximately 1-3 minutes.  When exposed to 
trypsin-versene cell membranes retract and cells appear round and refractile.  At this stage the 
sides of the culture dish were then gently tapped to dislodge cells.  In order to halt the action 
of trypsin-versene, twice the volume of cell-specific media was added to the culture dish 
containing cells.  Using a Pasteur pipette, the cell-suspension was gently agitated.  The 
cell-suspension was aspirated collected and centrifuged at 100 x g for 5 minutes at room 
temperature (RT) (Megafuge 1.0 R; Heraeus, Germany).  The supernatant was discarded and 
the pellet re-suspended in 1-2 ml fresh, pre-warmed culture media.  The cell-suspension was 
again gently agitated to disassociate cell clumps.  A cell count and cell viability assay, 





Figure 2.1: Phase-contrast photomicrograph of dMVECs in culture, 100x magnification 
 
 





When cells were sub-cultured, the cell-suspension volume necessary to obtain the required 
seeding density was calculated and tissue culture dishes plated as described in section 2.2.4.  
For all experimental purposes, endothelial cells were used between passages 4 and 9.  If cells 
were to be frozen, dimethylsulfoxide (DMSO; Sigma), diluted in culture medium, was added 
to the cell-suspension to yield a final concentration of 10% DMSO (v/v).  Freezing densities 
depended upon cell lines, cell yield and cell numbers required for experimental work but 
were never less than 200 000 endothelial cells and 300 000 tumour cells.  DMSO-cell 
suspensions were stored in a volume of 1 ml per cryo-vial (Corning-Costar, USA); the 
cryo-vial was labelled and allowed to settle for a maximum of 30 minutes at RT.  They were 
subsequently transferred and frozen in an ultra-freezer at -85oC.  A cell log was maintained to 
monitor cell banks.   
 
2.2.5.1   Cell count and cell viability 
Cell counts and viability assays were performed using a haemocytometer and the trypan blue 
exclusion test.  A 1:1 ratio of cell-suspension and trypan blue was loaded onto the 
haemocytometer.  Cells were counted under a light microscope (DMLB; Leica, Germany).  
Non-viable cells were distinguished from viable cells as they were blue in colour due to dye 
uptake.  Viable and non-viable cells were counted in a total of eight (1 mm) quadrants to 
obtain an average score.  Due to the toxicity of trypan blue, cell counts were performed 
between 5 and 10 minutes after the addition of the dye.  Cell concentration and viability was 
determined using the following formulas: 
 
Cell concentration = no. of cells / no. of quadrants x 104 x 2 
Percentage viability = no. of viable cells / total no. of cells x 100 
53 
 
2.3 Angiogenic and tumourigenic models 
2.3.1 Proliferation assays 
2.3.1.1   Experiments 
The effect of CM from one cell line on the proliferation of another was investigated using the 
MTT cell proliferation assay.  Increasing concentrations of DU145 prostate tumour CM were 
added to dMVECs and their proliferation determined after 24 hour experimental exposure.  
BKR antagonists were tested for their ability to inhibit CM-stimulated proliferation, while 
BKR agonists were investigated for their mitogenic potential on dMVECs.  In addition, the 
effect of VEGF on dMVEC proliferation was examined.  As a method control, the effect of 
serum on dMVEC growth, was also investigated (Appendix B1).  CM from other tumour cell 
lines was also examined for angiogenic potential on dMVECs (Appendix D2) as well as on 
an alternate endothelial cell line, HUVECS (Appendix E).   
In prostate tumour cell proliferation assays, BKR agonists were investigated for their 
mitogenic potential on DU145 cells.  Next, a B1R antagonist was tested for its ability to 
inhibit agonist-stimulated growth.   
 
2.3.1.2   Background 
MTT is a yellow tetrazolium salt that produces water insoluble, blue formazan crystals when 
cleaved by mitochondria (145, 160).  After the addition of a detergent such as DMSO this 
blue colour can be solubilised and subsequently quantified using a spectrophotometer (161).  
This method is universally used to evaluate cellular proliferation since metabolically active 
cells contain mitochondria that enable formazan production (145). 
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2.3.1.3   Protocol 
Endothelial cells (dMVECs or HUVECs) and tumour cells (DU145) were grown to 
confluency in culture dishes, sub-cultured and re-seeded in 96-well culture plates (Corning) 
at a density of 4500 cells/cm2.  For the production of CM, tumour cells (DU145, HeLa and 
N2α) cells were seeded at 4000 cells/cm2 in P60 culture dishes.  CM from tumour cells was 
generated over a 24 hour period.  Upon attaining approximately 60% confluency (typically 
2-3 days) in 96-well plates, tumour and endothelial cells were ready for the addition of test 
substances.  The cell-specific growth medium was replaced with CM, BKR agonists, BKR 
antagonists or VEGF, and incubated at 37oC, 5% CO2 for 24 hours following which the MTT 
assay was performed.   
 
Modification of conditions 
Previous studies investigating the mitogenic effects of CM differed in many respects in terms 
of their CM models.  Therefore, the following modifications were employed to the tumour 
and endothelial cell environment to incorporate the methodologies of previous studies:  
1. Tumour cells were grown in their respective cell-specific medium (DMEM) and then 
gradually weaned onto a common medium (EGM-2), that would facilitate growth of 
both tumour and endothelial cells. 
2. The dMVECs were serum-starved for 24 hours, in 0% FBS/EGM-2, prior to the 
addition of CM as suggested by a previous report (162).  The function of serum-free 
media appears to be two-fold: 1) to eliminate the effect of FBS - a direct contributor 
to cell proliferation and 2) to align the cells into the G0 phase of the cell cycle (163). 
3. DU145 cells were additionally serum-starved in 0% FBS/EGM-2, as suggested by 
previous studies (163-165).  CM was, therefore, generated in serum-free medium.  
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4. Low-serum conditions (0.5% FBS/EGM-2) were applied to dMVECs and DU145 
cells as suggested by a previous study (151). 
5. CM was generated over 24, 48 or 72 hours to explore the possibility that extended 
time periods of exposure to cultured cells would produce CM containing greater 
concentrations of angiogenic factors. 
6. The concentration range of CM was increased. 
7. In addition to the above modifications, the CM model was expanded to include 
alternate endothelial (HUVEC) and tumour (HeLa and N2α) cell lines to serve as 
comparative controls. 
 
2.3.1.4   Experimental and control treatments 
Endothelial cells 
CM of increasing concentrations (0, 10, 25 and 50%) was prepared by filtering the spent 
media through a 0.22 μm pore syringe filter (LASEC, SA) and, thereafter, diluted 
accordingly with fresh EGM-2.  For each concentration of CM/EGM-2, DMEM/EGM-2 
controls were run simultaneously to compensate for the effects of different media on dMVEC 
growth.  Control treatments contained 0, 10, 25 and 50% fresh DMEM, diluted accordingly 
with EGM-2.  Maximum concentrations of 50% CM was tested since it was ascertained in 
previous work in our laboratories that concentrations greater than 50% proved to be 
detrimental to cell growth (166). 
 
When the conditions were further modified, 12.5, 25 50, 75 and 100% CM was prepared by 





For agonist experiments, B1R or B2R agonists were added at concentrations of 50, 250, 500 
and 1000 nM to EGM-2.  EGM-2 served as a relevant baseline control.  For antagonist 
experiments, B1R or B2R antagonists were added at concentrations of 0.5, 1, 2.5, 5 and 
10 µM to endothelial cells 30 minutes prior to the addition of 50% CM.   
 
In the method controls, cells were administered serum-free EGM-2 or VEGF at 
concentrations of 1, 10, 50 and 100 ng/ml.  VEGF was added to various basal media:  
1. 5% FBS/EGM-2  
2. 0% FBS/EGM-2  
3. 5% FBS/EBM-2  
4. 0% FBS/EBM-2  
 
Tumour cells  
B1R or B2R agonists were added at concentrations of 10, 50 or 100 nM to DMEM for 
DU145 agonist experiments, while for antagonist experiments, 10 µM B1R antagonist was 
added to DU145 cells 30 minutes prior to the addition of the B1R agonist.  VEGF was added 
at concentrations of 10, 50 and 100 ng/ml.  DMEM served as a baseline control. 
 
2.3.1.5   MTT assay 
The MTT assay was used to determine dMVEC or DU145 proliferation after exposure to 
tumour CM, BKR agonists, BKR antagonists or VEGF.  MTT salt (Sigma, St. Louis, USA) 
was dissolved in pre-warmed HBSS at 5 mg/ml by incubation at 37oC for 10 min, and 
thereafter filtered through a 0.22 µm filter.  A volume of 10 µl MTT solution was added to 
100 µl of cell-specific medium (EGM-2 or DMEM) for every well to be assayed.  The 
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experimental and control medium in the wells were aspirated and discarded.  Next, 110 µl of 
the MTT-cell-specific medium was added to each well and incubated for 4 hours at 37oC, 
5% CO2.  After incubation, the MTT-cell-specific medium was aspirated and discarded and 
then 100 µl of DMSO was added to each well to dissolve the precipitate.  The 96-well plate 
was further incubated for 1 hour at 37oC, 5% CO2 following which absorbance was read at a 
wavelength of 595 nm (reference 655 nm) using a microplate reader (Model 3550; Biorad, 
UK). 
 
2.3.1.6   Data presentation 
For assays in which DMEM CM was diluted with EGM-2, net proliferation was calculated by 
subtracting the proliferative effect of fresh DMEM/EGM-2 from the proliferative effect of 
CM.  For all other MTT assays, proliferation was expressed in each experimental set as a 
percentage of the relevant control (expressed as 100%). 
 
2.3.2 Migration assays 
2.3.2.1   Experiments 
The ability of prostate tumour CM to stimulate another important event in angiogenesis 
namely endothelial cell migration, was investigated.  BKR agonists, in the presence or 
absence of CM, were also tested for their pro-migratory effect on dMVECs.  Additionally, 
the inhibitory effect of a B1R antagonist was tested by pre-incubation of dMVECs prior to 
stimulation with basal media, DU145 CM or B1R agonist.  VEGF was also tested for its 
pro-stimulatory effect on dMVEC migration.  In method controls the effect of serum and 
other media types were investigated (Appendix B2). 
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In DU145 cell migration assays, the ability of DU145 CM to stimulate cell migration in an 
autocrine manner was tested.  BKR agonists were also examined for their pro-migratory 
potential.  Next, a B1R antagonist was investigated for its ability to inhibit baseline, CM or 
agonist-mediated migration. 
 
2.3.2.2   Background 
The modified Boyden chamber assay is frequently used to measure cell motility (146).  The 
chamber consists of an upper (containing cells) and lower compartment (containing test 
substances) separated by a porous membrane (145).  Cells that migrate across the membrane, 
in response to the test substance, can then be quantified using Calcein-acetomethylester 
(Calcein-AM).  Uptake of Calcein-AM by cells that have migrated causes internal cleavage 
of the AM component producing free fluorescent calcein (155).  The fluorescence can then be 
quantified using a standard curve and correlated with cell number.  For our experiments we 
used a 96-well HTS Transwell® plate (Corning, NY, USA) containing an 8 µm polyester 
membrane.  Figure 2.3 illustrates the modified Boyden chamber model used in the present 
study. 
 
2.3.2.3   Protocol 
Endothelial or tumour cells were grown to confluence, trypsinised and centrifuged.  The 
supernatant was aspirated and cells were suspended in their respective serum-free, growth 
factor-free medium.  A cell count was performed and the cell density adjusted to  
400 000 cells/ml.  For dMVEC migration assays test substances (CM, VEGF, BKR agonists 
and a B1R antagonist) were prepared in 10% FBS/DMEM.  For DU145 migration assays, 
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Test substances 
Time 0 16 hours 
overnight 
Figure 2.3: Modified Boyden chamber as used in the present study 





prepared in 5% FBS/DMEM.  These concentrations of FBS were optimised for dMVEC and 
DU145 cell lines to ensure a baseline migration, over which additional effects of test 
substances could be measured.  Using the access ports, 150 µl of test medium was added to 
the lower wells of the plate.  Thereafter, 20 000 (50 µl) dMVEC or DU145 cells were added 
to the upper wells of the Boyden chamber.  For antagonist experiments, cells were pre-treated 
with 10 µM BKR antagonist for 30 minutes before addition to the upper chamber.  To 
compensate for background, cells were omitted from at least 3 blank wells.  The plate was 
incubated overnight at 37oC, 5% CO2. 
 
2.3.2.4   Experimental and control treatments 
Endothelial cells 
CM was extracted as described for endothelial cell proliferation assays and filtered and 
diluted to yield test concentrations of 0, 50 and 100%.  B1R or B2R agonists were added at a 
concentration of 100 nM while the B1R antagonist was added at a concentration of 10 µM.  
In addition, the BKR agonists were added to 100% CM to investigate possible synergistic 
effects.  Serum-free DMEM and 10, 50 and 100 ng/ml VEGF were used as method controls.  
Due to the large number of endothelial cells required for migration assays, the concentration 
range of stimulants were limited to those that demonstrated maximal stimulation in these and 
previous studies.  Further, antagonist experiments were performed using only a B1R 
antagonist due to the lack of effect demonstrated by the B2R in proliferation and migration 






CM at concentrations of 0, 10, 50 and 100% was prepared as described for endothelial cells.  
B1R or B2R agonists were added at concentrations of 10, 50 and 100 nM while the B1R 
antagonist was added at a concentration of 10 µM.  Similarly, serum-free DMEM was used as 
a method control.   
 
2.3.2.5   Fluorescence detection 
Following overnight incubation, cells remaining in the upper chamber were aspirated and 
each well was washed with 100 µl of HBSS.  The medium in the bottom chambers was 
aspirated and each well washed twice with 200 µl HBSS.  DMSO (25 µl) was added to a 
50 µg vial of Calcein-AM (BD Biosciences) to make a 2 mM working solution.  Calcein-AM 
(10 µl of 2 mM) was added to 10 ml pre-warmed Cell-Dissociation Solution (CDS; Sigma, 
St. Louis, USA) and kept in the dark prior to use.  Using the access ports, 100 µl of 
CDS/Calcein-AM was added to each well of the bottom chamber.  The device was assembled 
and incubated for 30 minutes at 37oC, 5% CO2.  It was then gently tapped 10 times on the 
sides to aid dissociation and incubated for a further 30 minutes.  The top chamber was 
removed, the bottom receiver plate was gently swirled to mix the solution and read using a 
fluorescent top reader at 485 nm excitation, 520 nm emission (Optima; BMG, Germany). 
 
2.3.2.6   Standard curve 
A standard curve was run concurrently with each experiment to extrapolate and quantify the 
number of cells that had migrated.  Cell densities of 20000, 10000, 5000, 2500, 1000 and 500 
were prepared by serial dilutions.  Cells were seeded in triplicate into the bottom chamber of 
the 96-well HTS Transwell® plate (Corning, NY, USA) and suspended in 100 µl CDS 
containing 2 mM Calcein-AM at a ratio of 1 ml CDS: 1 µl Calcein-AM.  The plate was 
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incubated for 1 hour and subsequently read using a fluorescent top reader at 485 nm 
excitation, 520 nm emission (Optima; BMG, Germany).   
 
2.3.2.7   Data presentation 
Values for experimental and standard curve conditions were averaged.  The plate background 
was then subtracted from each value.  A standard curve of relative fluorescent units (RFU) 
versus number of cells was plotted.  A trend line was inserted and a straight line equation 
generated.  Using the RFU value for each condition, the number of cells migrated was 
extrapolated from the graph.  This value was expressed as a percentage of the value obtained 
for the control. 
 
2.4 Conditioned medium analysis 
2.4.1 Enzyme-linked immunosorbent assay 
2.4.1.1   Background 
An indirect sandwich enzyme-linked immunosorbent assay (ELISA) was performed in the 
present study to determine the concentration of TK in DU145 CM.  ELISAs are useful tools 
for the detection of particular proteins in a sample (167).  The underlying principle of an 
ELISA is the detection of antigen-antibody complexes by enzymatic conversion of a 
colourless substrate to a measurable coloured product that can then be quantified using a 
spectrophotometer (168).   
 
2.4.1.2   Samples and controls 
Recombinant human kallikrein-1 (TK) was diluted in phosphate buffered saline (PBS) to 
concentrations of 40, 20, 10, 5, 2.5, 1.25 and 0.625 ng/ml to generate a standard curve  
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(Figure F1, Appendix F).  CM, generated in serum-free EGM-2 or 5% FBS/EGM-2, over 24, 
48 and 72 hours comprised the experimental samples while fresh EGM-2 medium (serum-
free and 5% FBS) were used as controls.  PBS served as a negative control.   
 
2.4.1.3   Protocol 
The TK ELISA was performed as described by Naidoo (2005) and Wright et al. (2008) with 
a few modifications (119, 122).  Reagents were prepared as described in Appendix A.  Goat 
anti-human TK antibody was loaded into each well of a cold, 96-well polystyrene microtitre 
ELISA plate (100 µl/well) and incubated at 4oC overnight.  Unbound antibody was then 
removed by washing each well with 250 µl wash buffer, 3 times for 3 minutes each at RT.  
To prevent non-specific binding, 300 µl milk blocker was added to each well and incubated 
for 30 minutes at RT.  Each well was again washed with wash buffer and incubated with milk 
blocker as previously.  Thereafter, 100 µl of samples, controls and standards were loaded 
onto the microtitre plate in triplicate.  The plate was then sealed with parafilm M (Whatman, 
UK) and incubated in a shaking water bath (Tecator, UK) bath at 37oC for 1 hour.  Wash 
steps with wash buffer were then repeated to remove unbound antigen.  The secondary 
antibody, rabbit anti-human immunoglobulin G (IgG) TK antibody (100 µl) was added to 
each well and the plate was then parafilmed and placed in a shaking waterbath at 37oC for 
1 hour.  Thereafter, the wells were washed with wash buffer, 3 times for 3 minutes each after 
which anti-rabbit IgG-alkaline phosphatase conjugate (Sigma, St. Louis, USA) was added to 
all wells.  The plate was again incubated in a shaking waterbath at 37oC for 1 hour and the 
wells subsequently washed with wash buffer, 3 times for 3 minutes.  Finally, chromogenic 
di-sodium paranitrophenyl phosphate substrate (pNPP; Sigma), diluted in substrate buffer 
was added to all wells.  The plate was incubated at RT in the dark until a yellow product 
developed and the highest absorbance measured ranged between 1 and 1.5 units 
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(approximately 30-40 minutes).  Absorbance was read using a Microplate Reader 3550 
(Biorad, UK) at a wavelength of 405 nm.   
 
2.4.1.4 Data presentation 
Values for standards, samples, media controls and negative controls were averaged.  The 
mean negative control was then subtracted from each value.  A standard curve of absorbance 
vs concentration of TK was plotted.  A trend line generated a straight line equation.   
 
2.5 Statistical analysis 
Proliferation assays were performed in quadruplicate while migration assays were performed 
in triplicate.  The repetitions for each experiment are indicated below each figure.  Cell 
proliferation and migration are expressed as a percentage of the non-stimulated control 
(regarded as 100%).  Results are illustrated in column graphs indicating the mean standard 
error of the mean (SEM).  Error bars are absent where sample sizes were too low.  In some 
experiments inhibition in proliferation or migration was observed after addition of test 
substances.  In order to represent this inhibition, the y-axis of graphs frequently begin with 
values below 100%.  A bio-statistician was consulted regarding the most appropriate data 
analysis techniques.  One-way analysis of variance (ANOVA) was used to test for statistical 
significance between multiple concentration groups followed by Dunnett’s post-hoc testing 
while Student’s t-test was used for comparison between two groups.  A p-value <0.05 was 
considered statistically significant.  Statistical analysis was performed using the software 












CHAPTER 3 - RESULTS 
3.1 Endothelial cells (dMVECs) 
3.1.1 dMVEC proliferation 
3.1.1.1   Effect of VEGF 
Generally VEGF caused increased proliferation of dMVECs (Figure 3.1.1.1).  This effect was 
greatest in the most rudimentary medium, free of FBS or growth factors (0% FBS/EBM-2), 
where after a small inhibition at 1 ng/ml, there was a dose-dependent increase with a 
maximum stimulatory effect of 20.8% at 100 ng/ml (Figure 3.1.1.1D).   
 
3.1.1.2   Effect of DU145 CM 
When dMVECs were challenged with increasing concentrations of DU145 CM, a statistically 
significant, although small, increase was observed (Figure 3.1.1.2).  At a concentration of 
50% CM proliferation increased by a mean of only 7.9%.  Again this was statistically 
significant (p<0.05); however, the effect was too small to indicate any scientific relevance. 
 
3.1.1.3   Effect of 50% CM on dMVECs pre-incubated with BKR antagonists 
Figure 3.1.1.3 shows the effect of increasing concentrations of B1R and B2R antagonists on 
the proliferation of dMVECs challenged with 50% CM.  Only a B2R antagonist at 
concentrations of 2.5 and 10 µM inhibited any effect of CM, although this was marginal and 
statistically insignificant.  In fact, although to a very small degree, other concentrations 
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Figure 3.1.1.2: dMVEC proliferation in response to DU145 CM 
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Figure 3.1.1.3: dMVEC proliferation following pre-incubation with BKR antagonists 
and challenge with 50% CM 
Baseline control is dMVEC stimulated by 50% CM (regarded as 100% proliferation). 
n=4 (4 replicates each) 
   (µM) 
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3.1.1.4   Effect of BKR agonists 
The B1R agonist stimulated endothelial proliferation in the concentration range 250 to 
1000 nM but only by 5-6% (Figure 3.1.1.4).  The B2R agonist did not stimulate endothelial 
cell proliferation at any concentration (Figure 3.1.1.4).   In fact, neither the B1R nor the B2R 
agonist had any significant effect on endothelial cell proliferation.   
 
3.1.2 dMVEC migration 
3.1.2.1   Effect of DU145 CM with or without an antagonist 
Addition of increasing concentrations of DU145 CM to the lower wells of the Boyden 
chamber did not stimulate dMVEC migration (Figure 3.1.2.1A).  In fact, 100% CM 
significantly inhibited dMVEC migration (p<0.05). 
 
Pre-incubation of dMVECs with 10 µM B1R antagonist had little influence on the effect of 
DU145 CM but it inhibited basal migration (in absence of CM) (Figure 3.1.2.1B). 
 
3.1.2.2   Effect of a B1R agonist with or without an antagonist 
Addition of a B1R agonist inhibited migration, while pre-treatment of dMVECs with 10 µM 
B1R antagonist before the addition of agonist caused further inhibition (Figure 3.1.2.2).  
When the agonist was added with CM there was statistically significant inhibition which was 
exaggerated even further by pre-incubation with 10 µM B1R antagonist (p<0.05)  
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Figure 3.1.1.4: dMVEC proliferation in response to B1R and B2R agonists 


























Figure 3.1.2.1A: dMVEC migration in response to DU145 CM 

























Figure 3.1.2.1B: dMVEC migration in response to DU145 CM and a B1R antagonist  
n=3 (3 replicates each) 
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Figure 3.1.2.2: dMVEC migration in response to CM, a B1R agonist and antagonist  





3.1.2.3   Effect of a B2R agonist 
Addition of the B2R agonist to the lower wells of the modified Boyden chamber inhibited 
dMVEC migration (Figure 3.1.2.3).  When 100% CM was also present statistically 
significant inhibition was observed although this was similar to migration in response to 
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Figure 3.1.2.3: dMVEC migration in response to CM and a B2R agonist 
*p<0.05; n=3 (3 replicates each) 
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3.2 Tumour cells (DU145) 
3.2.1 DU145 cell proliferation 
3.2.1.1   Effect of BKR agonists with or without an antagonist 
All concentrations of the B1R agonist tested stimulated DU145 proliferation.  This effect was 
greatest at a concentration of 10 nM where a statistically significant increase of 11.9% was 
observed (p<0.05) (Figure 3.2.1.1A).  Pre-incubation with a specific B1R antagonist 
significantly inhibited proliferation by 13-18% for the B1R agonist concentration range 
10-100 nM (p<0.05) (Figure 3.2.1.1A). 
 
The B2R agonist did not have any marked effect on DU145 proliferation at any concentration 
(Figure 3.2.1.1B).   
 
3.2.2 DU145 cell migration 
3.2.2.1   Effect of DU145 CM with or without an antagonist  
DU145 CM in the lower wells of a modified Boyden chamber did not prove to be a migratory 
stimulus for the DU145 cells (Figure 3.2.2.1).  In fact, DU145 CM significantly inhibited 
migration at 50% CM (p<0.05).  Pre-treatment of the cells with a B1R antagonist 
significantly inhibited cell migration at 0% CM but had no inhibitory effect when the 
concentration of CM was increased; however, at 100% CM the B1R antagonist stimulated 
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Figure 3.2.1.1A: DU145 proliferation in response to a B1R agonist and antagonist 
























Figure 3.2.1.1B: DU145 proliferation in response to a B2R agonist  
n=6 (4 replicates each) 
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Figure 3.2.2.1: DU145 migration in response to DU145 CM and a B1R antagonist 
* p<0.05; n=6 (3 replicates each)  
10 µM B1R Antagonist 
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3.2.2.2   Effect of BKR agonists with or without an antagonist 
The B1R agonist stimulated cell migration in the concentration range 10-50 nM (Figure 
3.2.2.2A).  A statistically significant, maximum increase of 23.9% was observed at 50 nM 
(p<0.05).  Pre-incubation of cells with a B1R antagonist (10 µM) abolished the stimulatory 
effect of the B1R agonist at concentrations of 10 and 50 nM.  This inhibitory effect was 
found to be statistically significant (p<0.05) (Figure 3.2.2.2A).   
 
All concentrations of B2R agonist stimulated cell migration although not significantly.  A 
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Figure 3.2.2.2A: DU145 migration in response to a B1R agonist and antagonist 























Figure 3.2.2.2B: DU145 migration in response to a B2R agonist  
n=8 (3 replicates each) 
 










CHAPTER 4 - DISCUSSION 
The KKS in endothelial cells 
The principal aim of this study was to investigate the kinin system within a controlled 
angiogenic environment.  Previous work on CM models in our laboratory found that 
increasing the concentrations of prostate tumour CM up to 50% significantly stimulated 
micro-vascular endothelial proliferation by as much as 40% (119).  In addition, they showed 
increased TK production by dMVECs challenged with CM and speculated that the KKS may 
be involved in up-regulated endothelial cell activity in angiogenesis.  That postulate provided 
the impetus for the present study.   
 
In the present study, although the addition of DU145 CM elicited a statistically significant 
increase in dMVEC proliferation, it was very small (<10%).  This result was not consistent 
with the findings of Wright et al. (2008).  In addition, modification of the endothelial and 
tumour growth environment with the use of low- and serum-free medium (as suggested by 
previous studies) did not result in a more significant positive effect on dMVEC proliferation 
(see Appendix D1).  This inability to reproduce the findings of Wright et al. (2008), despite 
experiments being performed under the same laboratory conditions as well as consequential 
attempts to modify experimental conditions, was surprising.  The reason for this lack of 
reproducibility remains unclear; however, no other previous studies appear to confirm the 
work of Wright et al. (2008), and it would have been advantageous had the data set of that 
project been larger.  
 
On careful examination of the literature, similar studies using the CM model to investigate 
the effects of soluble substances secreted by tumours have also produced conflicting data 
(119, 122, 151, 163, 164, 169, 170).  For example, Hewett (2001) tested the CM from various 
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carcinomas on human mammary micro-vascular endothelial cells (HuMMEC), reporting that 
just one CM (breast carcinoma MDA-MB-231) from eight different tumour types caused 
significant endothelial proliferative activity (169).  Hepburn et al. (1997) found that DU145 
CM had no proliferative effect on the micro-vascular cell line, bovine adrenal cortex 
endothelial cells (BACE) (164).  That group further tested five other prostatic tumour cell 
lines on BACE and found that only one (Ten 12) stimulated proliferation.  The fact that those 
investigators have shown that the CM of only one prostatic cell line stimulated  
micro-vascular endothelial cell growth whilst CM from numerous other prostatic cell lines 
did not, is supportive of our findings. 
 
While we initially selected micro-vascular cells (dMVECs) for use in proliferation assays, as 
they provide a more suitable in vitro model to mimic angiogenesis in vivo, they showed little 
angiogenic activity in the present study.  Therefore, in an attempt to fully explore the 
pro-angiogenic effects of tumour CM, other endothelial and tumour cell lines were also 
investigated.  In these experiments we used an alternate endothelial cell line (HUVEC) and 
found that (i) cervical carcinoma (HeLa) CM showed no positive proliferative effect, 
(ii) DU145 CM demonstrated marginal increases, and (iii) brain neuroblastoma (N2α) 
showed the most promising mitogenic profile.  Similarly, other studies have found that 
neuroblastoma CM resulted in marked HUVEC proliferation compared to other tumour cell 
lines tested (122, 163).  Several other studies have also examined the proliferative effect of 
tumour CM on HUVECs (118, 122, 151, 164, 169).  It seems overall that micro-vessels are 
less responsive to tumour CM than large vessel endothelia (164, 169).  Naidoo (2005) 
reported that CM from HeLa cells increased proliferation by 93%, Hepburn et al. (1997) 
demonstrated that of six prostatic cell lines tested, two showed no endothelial proliferative 
activity, while Hewett (2001) found that of the tumour CM extracted from four small cell 
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lung carcinomas (SCLC) and four breast adenocarcinomas, three SCLC and two breast 
adenocarcinoma cell lines did not significantly enhance endothelial proliferation (122, 164, 169). 
 
Numerous in vitro studies have implicated the KKS in angiogenesis, Wright et al. (2008) and 
Naidoo (2005) postulated that TK secreted by both endothelial and tumour cells, cleaved 
kininogens to form active kinin peptides, subsequently mediating their pro-mitogenic effects 
via their cognate receptors (119, 122).  The possible role of the KKS in angiogenesis is further 
substantiated by several in vivo reports involving mouse models (136, 139-141).  One particular 
study demonstrated that TK gene delivery resulted in a heightened ischemia-induced 
angiogenic response (136).  Further, angiogenic suppression was reported in that and other 
mouse models with the use of selective BKR antagonists (136, 140).   
 
In the present study, the small proliferative effect of DU145 CM on dMVECs is not likely to 
be due to the KKS.  Specific blocking of both the membrane-bound B1R and B2R with 
antagonists failed to alter the effects of the CM, suggesting this effect was not directly 
kinin-mediated.  Our investigations also revealed that stimulation of either the B1R or B2R 
with agonists did not significantly induce endothelial cell proliferation.  Further, selective 
BKR agonists as well as DU145 CM did not demonstrate any influence in endothelial cell 
migration, another important event in the angiogenic cascade.  In fact, BKR agonists 
inhibited migration.  This inhibitory effect was further exaggerated when combined with CM 
and/or antagonists suggesting possible interference of compounds with basal migration.  
Interestingly, although a B1R agonist failed to stimulate endothelial cell migration, a B1R 
antagonist was found to inhibit basal migration.  It may be possible that a B1R antagonist 
inhibits FBS induced basal migration by some mechanism yet to be elucidated.  DU145 CM 
was also found to inhibit endothelial cell migration.  Since FBS directly stimulates migration, 
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this inhibitory effect is most likely due to the depletion of FBS in CM due to uptake by 
proliferating DU145 cells in culture.  In support of this hypothesis, it was found that when 
CM was generated in serum-free medium and subsequently supplemented with FBS the 
inhibitory effect was not as marked (See Appendix B2).  
 
Other studies have demonstrated different endothelial cell proliferation results in response to 
BKR agonists when compared to the present study result.  Emanueli et al. (2002) and 
Morbidelli et al. (1998) reported increases in endothelial cell proliferation with the addition 
of a B1R agonist (110, 171).  However, consistent with our findings, Morbidelli et al. (1998) 
also demonstrated that a B2R agonist did not cause any significant increase in proliferative 
activity (110).  Similarly, that group showed that endothelial cell migration was not 
stimulated by selective BKR agonists or BK, a finding consistent with ours.  Interestingly, 
those studies that have demonstrated increased proliferative activity with the use of B1R 
agonists, were based on the larger blood vessels HUVECs and coronary venular endothelial 
cells (CVEC), with increased exposure periods of 48 and 72 hours compared to the 24 hour 
period in the present study.   
 
Kinin receptor mediation in angiogenesis has been proposed in numerous previous studies 
(110, 171, 172).  It is known that the B2R is ubiquitously expressed on endothelial cells, 
while the B1R is pathologically induced (110, 173).  Parenti et al. (2001) demonstrated that 
B1R activation is involved in endothelial cell proliferation, but B2R activation indirectly 
contributes to angiogenesis via mediation of inflammatory processes (172).  Further, the 
commercially-obtained dMVECs used in the present study were isolated from a 42 year old 
female, and, since adult endothelium is maintained in a quiescent state, there is little or no 
angiogenesis in normal tissues (174).  Interestingly, Naidoo (2005) was able to demonstrate 
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TK secretion from HUVECs although Wright et al. (2008) was unable to do so in a similar 
study involving dMVECs (119, 122).  The Wright group postulated that while endothelial 
cells of micro-vascular origin are involved in angiogenesis in vivo, they secrete little TK 
physiologically.  These various limitations and unclear implications may provide a plausible 
explanation for the lack of pro-angiogenic effects demonstrated by kinins in our model.  
 
Tumour CM consists of a myriad of pro- and anti-angiogenic factors that remains to be fully 
elucidated (164).  As a result, tumour neo-vascularisation may be a consequence of several 
angiogenic factors functioning synergistically as opposed to a single, isolated factor (175).  In 
the present study we were able to demonstrate the proliferative potential of VEGF, a 
universally accepted mitogen, on dMVECs thereby verifying their physiological integrity.  
Studies have shown that tumour cell cultures comprise elevated concentrations of VEGF, 
IL-8 and bFGF, pro-angiogenic factors with potent mitogenic potential (48, 55, 163, 164, 
175).  Hepburn et al. (1997) reported the expression of bFGF and VEGF in the CM of 
numerous prostatic cell lines including DU145, while Ferrer et al. (1998) found significant 
levels of VEGF and IL-8 immuno-staining in prostate cancer tissue compared to normal 
prostate tissues (164, 175).  Further, Hepburn (1997) found that the level of bFGF in the CM 
of the only tumour cell line (Ten 12) that stimulated micro-vascular growth was at least 
3-fold greater when compared with other prostatic cell lines tested and postulated that the 
up-regulation of this growth factor was responsible for the resultant endothelial stimulation 
(164).  In addition, other angiogenic factors such as TGF-α and TGF-β are produced by 
prostate cell lines (48, 164).  mRNA expression of TGF-α and TGF-β has been reported in 
several prostatic cell lines (176, 177).  Previous studies have reported stimulatory effects on 
endothelial cells with TGF-α while TGF-β inhibited endothelial cell proliferation in vitro 
(164, 178).  Interestingly, bFGF can alter the inhibitory effect of TGF-β on endothelial cells, 
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functioning synergistically to stimulate invasion (179).  Therefore, it appears that our results 
and other studies concur with the generally-accepted principal that initiation of angiogenic 
events requires regulation of various systems that work in concert to induce endothelial 
growth.  
 
In contrast to some previous studies, the present study was unable to implicate the KKS in 
angiogenesis, and we speculate that the ideal pathological in vivo conditions may not have 
been adequately reconstructed in the in vitro tumour CM model and, therefore, the 
participation of the KKS in angiogenesis could not be entirely defined.  Thus, it appears that 
the marginal mitogenic potential of DU145 CM demonstrated in the present study probably 
relates to the balance of pro- and anti-angiogenic factors in DU145 CM as well as to 
endogenous production by endothelial cells and to the synergism of such factors.   
 
KKS in tumour cells 
Up-regulated expression of kallikreins and kinins in various cancers, including prostate 
cancer, have implicated the KKS in tumourigenesis (109, 127).  We used DU145 cells as a 
model of hormone-insensitive prostate cancer in the present study, and postulated that BK 
may be involved in tumour cell growth and migration.  This project is the first to show, in 
DU145 cells, that a specific B1R agonist could significantly increase proliferation.  In order 
to prove the effect to be B1R-regulated we used a B1R antagonist which effectively 
abbrogated this pro-angiogenic effect.  This result is consistent with other prostate cancer 
reports (11, 109, 132).  Although expression of BKR has been demonstrated in both normal 
and malignant tissues, numerous studies have shown that kinin expression is specifically 
up-regulated in pathological states (11, 101, 124, 180).  Further, Taub et al. (2003) found that 
pre-malignant and malignant prostate tissues exhibit an altered kinin expression profile 
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compared to their normal counterparts (11).  Various researchers have shown that the 
addition of BK and specific BKR agonists enhances growth of PC3 prostate cancer cells.  
This effect could then be abrogated following pre-incubation of cells with a specific B1R or 
B2R antagonist (11, 109, 132).  Based on similar results, some researchers have suggested 
that specific inhibition of the B1R may be of significant value to advanced prostate disease 
(11, 109).   
 
In contrast to the effect of B1R agonism, we found that the addition of a specific B2R 
agonist, at any concentration, resulted in no significant stimulation of DU145 cells.  This 
finding is inconsistent with another study where it was found that specific stimulation of the 
B2R enhanced the growth of prostate cancer PC3 cells (132).  However, our finding was not 
an unexpected outcome; indeed, Taub et al. (2003) also reported that while the B2R is 
ubiquitously expressed in both human benign and malignant prostatic tissue, the B1R is 
found only in pre-malignant and malignant prostate specimens (11).   
 
In the present study, we did note some variation in the extent to which a B1R agonist 
stimulated tumour cells when compared to previous work (11, 132).  The effect of BKR 
agonists on tumour cells in vitro are likely to be dependent on a number of factors; for 
example, the tumour type and conditions of experimental models.  It is possible that such 
variation could also be attributed to the different prostatic cell lines.  DU145 and PC3 cell 
lines are both classical epithelial cell lines of prostate cancer; however, they differ in their 
DNA profiles and cytogenetic analysis (158).  In addition, the exposure period in other 
experiments were notably longer (48 hours compared to 24 hours in the present study).  In a 
similar way,  Barki-Harrington and Daaka (2001), Barki-Harrington et al. (2003) and Taub et 
al. (2003) demonstrated that BK or BKR agonists were able to stimulate proliferation of PC3 
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cells; however, this could not be reproduced by Srinivasan et al. (2004) where neither PC3 
cells nor LNCaP cells (2 metastatic prostatic carcinomas) could be stimulated by the addition 
of BK (11, 109, 132, 181).  Srinivasan and colleagues attributed these discrepancies to 
differences in passage numbers of cells between the studies, reporting that BKR expression 
may be dependent on passage number and culture conditions.  Interestingly, Molina et al. 
(2009) found that proliferation measured by bromodeoxyuridine (BrdU) incorporation, 
increased 2-fold when MCF-7 breast cancer cells were stimulated with BK, while the 
addition of a B1R agonist induced a proliferative response by almost 4-fold compared to the 
untreated control (127).  This leads one to speculate that kinins may be involved in both 
androgen-independent (DU145) and oestrogen-sensitive (MCF-7) carcinomas.  Because 
kinins may potentiate the effects of other growth factors (bFGF and EGF) implicated in the 
development of hormone-independence, and up-regulated TK and kinins have been shown 
in several human cancers, the KKS is likely to play a role in the transformation of hormone-
dependent to hormone-independent tumour subtypes (110, 119, 182).  Wright et al. (2008) 
postulated that increased TK in the tumour micro-environment would support the mutation 
into a hormone-independent form (119).   
 
Tumour cell migration is fundamental to advanced cancer progression and metastasis (11).  In 
addition to expressing receptors for BK, tumour cells also promote the production of these 
receptor ligands, and BK has been identified as an autocrine growth factor in tumours (126).  
In the present study, DU145 CM did not stimulate DU145 migration.  In fact, it inhibited 
DU145 migration, an effect that is once again likely due to FBS depletion in the CM.  
Interestingly, the B1R antagonist inhibited basal DU145 migration but stimulated migration 
when pre-incubated with cells exposed to 100% CM.  It may be that the B1R antagonist 
inhibits FBS induced migration, whilst when FBS concentration is at its lowest (100% CM) 
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the antagonist stimulates migration by binding to some other pre-migratory receptor. 
Alternatively, perhaps the antagonist has the capacity to stimulate mitogenic pathways in a 
similar manner compared to receptor agonists.  Interestingly, a study performed by Drube et 
al. (2000) found that in some lung, colon and breast tumour cell lines a B2R antagonist acts 
as an agonist stimulating DNA synthesis (183).  These researchers suggested that the B2R 
antagonist may trigger the same signalling pathways as BK.   
 
Previous studies, including some in our laboratory, have shown increased expression of TK 
in prostate cancer as well as the presence of kinin peptides in ascitic tumour fluid (119, 124). 
Since DU145 CM did not stimulate DU145 migration and the level of TK was found to be 
undetectable in the CM of DU145 cells by ELISA (see Appendix F), the present study was 
unable to positively link CM, the KKS and migration.  However, we were able to 
demonstrate that the addition of a B1R agonist induced a positive chemotactic response, 
significantly stimulating DU145 cell migration.  Subsequent use of a B1R antagonist 
inhibited migration, further illustrating kinin receptor mediation.  These findings are 
consistent with previous work performed by Taub et al. (2003) where stimulation of the B1R 
was found to promote PC3 migration in the wound healing assay (11).  Pre-treatment with an 
antagonist abrogated that effect.  That study observed a 6-fold increase in tumour cell 
migration when stimulated with a B1R agonist whereas the present study noted an 
approximate increase of just 20%.  This variation may be largely attributed to differences in 
assays used to investigate migration as well as the cell lines that were tested.  The PC3 cell 
line is a highly metastatic prostatic carcinoma compared with DU145 which exhibits 
moderate metastatic potential (158).  Taub et al. (2003) also demonstrated the ability of 
kinins to induce prostate cancer PC3 invasion, with the use of a modified Boyden chamber, 
and showed specific stimulation of the B1R enhanced invasion by 3-4-fold (11).  In addition, 
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other components of the KKS have been shown to be involved in metastasis; Wolf et al. 
(2001) implicated TK in the metastasis of a breast carcinoma and found that this process 
could be significantly attenuated with the use of a TK inhibitor (121).  Naidoo (2005) also 
postulated that TK, released by a tumour mass, contributes to ECM remodelling thereby 
allowing expansion of the tumour.  Thus, the KKS may contribute to tumour invasion via TK 
activated MMPs as well as kinin receptor stimulation.   
 
Summary and conclusions 
In summary, it appears that CM from some prostate cancer cell lines stimulates micro-vascular 
endothelial cell proliferation whilst that from other prostatic cell lines does not.  In the present 
study the extent to which DU145 CM stimulated dMVEC proliferation was small.  Although 
our results did not support a role for the KKS in dMVEC proliferation and migration and hence 
angiogenesis, previous studies suggested that the KKS has a multifunctional role in 
angiogenesis and tumourigenesis.   
 
The present study was the first to show the involvement of the KKS in DU145 
tumourigenesis; we demonstrated that specific stimulation of the B1R increased tumour cell 
proliferation and migration, while pre-incubation with the relevant BKR antagonist abrogated 
this effect (Figure 4.1).  Therefore our results do support previous studies and suggest a 
possible role of BK in prostate pathology.  There is, therefore, compelling evidence for the 
involvement of the KKS in cancer and prostate cancer.  This may be more so in PC3 than 
DU145 tumours.  PC3 tumours are more aggressive and metastatic and it appears, therefore, 
that the effect of BK on growth and migration may be even greater.  However, even in 
hormone-independent cancers such as DU145, because few effective treatments are available, 
BKR antagonists should be considered plausible candidates in the development of alternate 
approaches to cancer therapy.   
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Figure 4.1: Proposed role of the KKS in prostate angiogenesis and tumourigenesis  
According to the prevailing concepts of angiogenesis and tumourigenesis (solid black lines) 
prostate tumour cells secrete both pro-and anti-angiogenic factors required for angiogenic 
stimulation.  In addition, TK, secreted by both endothelial and tumour cells, contributes to the 
activation of MMPs involved in ECM degradation, and cleavage of kininogens (LMWK and 
HMWK) to generate active kinin peptides.  Kinins mediate their mitogenic and invasive 
properties via their cognate receptors present on endothelial and tumour cells.  Tumour cells 
may also facilitate their own growth via endogenous kinin production.   
 
Results (broken blue, green and red lines) demonstrate that (i) BKR agonists did not appear to 
induce proliferation or migration in endothelial cells and (ii) specific stimulation of the of the 
B1R, but not the B2R, increased tumour cell proliferation and migration, while antagonism of 
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A1. TK ELISA reagents 
1. Coating Buffer - 0.015 M Na2CO3 (AR, Merck) and 0.04 M NaHCO3 (BDH 
Chemicals, England) dissolved in distilled, deionised water (ddH2O) and  
adjusted to pH 9.6 
2. PBS - PBS tablets (Sigma) dissolved in ddH2O to 0.01 M  
3. Wash Buffer - Tween 20 (Sigma) dissolved in 0.01 M PBS to  
PBS/0.05% Tween 20 
4. Milk Blocker - 5% fat free milk powder (Elite, SA) dissolved in 0.01 M PBS 
5. Substrate Buffer - 5 mM magnesium chloride (MgCl2,AR, Merck) and 10% di-
ethanolamine (Sigma) dissolved in ddH2O and adjusted to pH 9.6 
6. pNPP - pNPP tablets (Sigma) dissolved in substrate buffer to 1 mg/ml 
7. Goat anti-human TK IgG - diluted to 30 ng/ml in coating buffer 
8. Rabbit anti-human TK IgG - diluted to 25 ng/ml in milk blocker 
9. Anti-rabbit IgG alkaline phosphatase (Sigma): diluted 1:5000 in milk blocker 
 
Goat anti-human TK IgG and Rabbit anti-human TK IgG antibodies were previously raised 




B1. dMVEC proliferation assay control 
Effect of serum  
When the effect of cell dependency on serum as a control was tested, it was shown that when 
serum is removed from the growth medium, there was a significant reduction in proliferation 
by 42.2% (p<0.05) (Figure B1).   
 
B2. dMVEC migration assay controls 
Effect of serum and other media  
The effect of cell dependency on serum as a control was tested and it was demonstrated that 
when serum is completely removed from the stimulatory medium, migration was 
significantly inhibited by 82.1% (p<0.05) (Figure B2a).  Complete EGM-2, that which 
contains 5% FBS supplemented with growth factors, proved to be the optimal medium for 
migration, resulting in a 2.5-fold increase compared to 10% FBS/DMEM.   
 
 Effect of VEGF 
All concentrations of VEGF tested stimulated migration of dMVECs.  This effect was 





























Figure B1: dMVEC proliferation in response to serum 

























Figure B2a: dMVEC migration in response to serum and other media 






















Figure B2b: dMVEC migration in response to VEGF 
n=3 (3 replicates each) 
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Effect of serum-free CM post-supplemented with FBS 
DU145 CM was generated in serum-free DMEM over 24 hours to prevent FBS being 
depleted by the proliferating tumour cells.  Prior to addition to the bottom wells of the 
modified Boyden chamber, CM was extracted and supplemented with 10% FBS.  DU145 CM 
did not stimulate endothelial cell migration (Figure B2c), however the inhibitory effect was 
























Figure B2c: dMVEC migration in response to serum-free CM post-supplemented with 
FBS  




C1. DU145 cell proliferation assay control 
Effect of VEGF  
The mitogenic effect of VEGF on DU145 was tested at 10, 50 and100 ng/ml (Figure C1).  At 
concentrations of 10 and 100 ng/ml no stimulation was observed.  At 50 ng/ml an increase of 
1.2% was noted.   
 
C2. DU145 cell migration assay control 
Effect of serum and VEGF 
In order to control for serum as an endogenous stimulator, the effect of cell dependency on 
serum was tested (Figure C2).  It was shown that when serum is removed from the 
stimulatory medium, there was a significant reduction in relative migration by up to 47.5%.  
Spiking the system with 100 ng VEGF enhanced the positive migratory effect of FBS by 

























Figure C1: DU145 proliferation in response to VEGF 
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Figure C2: DU145 migration in response to serum and VEGF 





D1. Modification of conditions – Effect of DU145 CM on dMVEC proliferation  
Effect of EGM-2 
Under normal conditions, CM was generated in tumour cell-specific medium (DMEM) over a 
defined period of time (24 hours).  DMEM was replaced with a common medium EGM-2 
that was sustainable for both the metabolite-inducing cell cultures and the fastidious 
endothelial cells.  We applied the rationale that an increased generation time of CM (24 hours 
compared to 48 hours) would yield a more concentrated, pro-angiogenic blend.  Modifying 
these conditions did not, however, result in a positive trend in dMVEC proliferation (Figure 
D1a). 
 
Effect of dMVEC serum-starvation 
Since no effect on dMVEC proliferation was observed with EGM-2, the protocol was 
amended such that the dMVECS were serum-starved in 0% FBS/EGM-2 as suggested by a 
previous study (162).  There was, however, still no significant effect of DU145 CM 
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Figure D1a: dMVEC proliferation in response to DU145 CM generated in EGM-2 
 n=3 (4 replicates each) except for CM generated over 48 hours where n=2 (4 replicates each) 
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Figure D1b: dMVEC proliferation following serum-starvation of endothelial cells 
n=1 (4 replicates each) except for CM generated over 48 hours where n=2 (4 replicates each).   
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Effect of dMVEC and DU145 serum-starvation 
As there was still no significant effect on dMVEC proliferation when the dMVECs were 
serum-starved, we then serum-starved DU145 cells as suggested by previous studies (163, 
164, 169).  CM was, therefore, generated in serum-free medium over increasing time periods.  
No significant effect of DU145 CM (generated over 24, 48 or 72 hours) on dMVEC 
proliferation was observed (Figure D1c). 
 
Effect of low-serum  
Since serum-starvation had no effect on dMVEC proliferation, low-serum conditions (0.5% 
FBS/EGM-2) were applied to endothelial and tumour cells, as suggested by a previous study 
(151).  No proliferative effect of CM was demonstrated.  Cellular inhibition was, however, 
observed between 75% and 100% CM (Figure D1d).  
 
D2. Use of alternate tumour cell lines as controls 
Effect of HeLa CM 
Other tumour CM were tested for their pro-angiogenic properties on micro-vascular 
endothelial cells.  The addition of increasing concentrations of Hela CM, generated in 
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Figure D1c: dMVEC proliferation following serum-starvation of endothelial and 
tumour cells 
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Figure D1d: dMVEC proliferation following growth of endothelial and tumour cells in 
0.5% FBS/EGM-2 
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Figure D2a: dMVEC proliferation in response to HeLa CM 




Effect of N2α CM 
An additional control, a neuroblastoma cell line (N2α) was tested for its effect on dMVEC 
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Figure D2b: dMVEC proliferation in response to N2α CM 





E1. HUVEC proliferation results 
Effect of DU145, HeLa and N2α CM 
When an alternate endothelial cell line (HUVEC) was tested with DU145, HeLa and N2α 
CM, no positive proliferative effect was observed with HeLa CM.  DU145 CM showed a 
marginal increase of 4.9% at 25% CM.  CM from N2α cells showed the most promising 
proliferative profile producing a dose-dependent curve, demonstrating a maximum increase 



























Figure E1: HUVEC proliferation in response to DU145, HeLa and N2α CM 





F1. TK measurement (ELISA) 
The amount of immune-reactive TK was measured in the CM of DU145 cells.  It was 
observed that when data were extrapolated using the TK ELISA standard curve, TK 
concentrations were below zero, leading us to conclude that the level of TK released by 
DU145 cells was below the lower limit of sensitivity of the assay and could, therefore, not be 
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Figure F1: ELISA standard curve for TK 
Absorbance = 0.007 (concentration) + 0.0018 
Correlation co-efficient = 0.9984 
 
